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ABSTRACT 
Introduction:  Ovarian folliculogenesis occurs in a wave-like pattern of growth during the 
menstrual cycle. A better understanding of the role of estrogen in folliculogenesis may lead 
to the development of better contraceptive and fertility protocols. Aromatase inhibitors 
cause a transient decline in natural estrogen production. Multiple small doses of an 
aromatase inhibitor have been used during fertility therapy to induce dominant follicle 
growth and ovulation. 
Objectives:  Our objectives were to elucidate the effects of a single 20 mg dose of an 
aromatase inhibitor (Letrozole/FemaraTM) on folliculogenesis and test the hypothesis that an 
AI administered during defined times of the follicular phase or immediately after ovulation 
would result in atresia of the extant dominant follicle and initiate new wave emergence. 
Methods:  Healthy, reproductive age, female volunteers not taking hormonal contraceptives 
were recruited (n=41). Ultrasound examinations began on day 4 of the menstrual cycle (day 
1=first day of menses). Volunteers were randomized into 1 of 4 groups: treatment at a 
follicle diameter of 1) 12 mm, 2) 18 mm, 3) the first day following ovulation, or 4) control. 
Serial ultrasonography and phlebotomy were performed until ovulation in the subsequent 
cycle. Differences were analyzed using t-test, ANOVA, repeated measures ANOVA, or 
Kruskal-Wallis ANOVA where appropriate.  
Results:  The dominant follicle in all treatment groups ovulated. There were no differences 
among experimental groups for peak follicle diameter, follicular growth rate, endometrial 
thickness at ovulation, or inter-ovulatory interval. Maximum FSH concentrations in the 12 
mm, 18 mm and post-OV groups were 12.58 ± 1.41 mIU/mL, 18.62 ± 2.27 mIU/mL, 12.38 
± 1.10 mIU/mL, respectively. Maximum LH concentrations in the 12 mm, 18 mm and post-
OV groups were 16.20 ±2.06 mIU/mL, 40.43 ± 4.32 mIU/mL, 16.34 ± 2.59 mIU/mL, 
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respectively. The 18 mm group had higher FSH and LH concentrations (P < 0.02) compared 
to the 12 mm and post-OV groups.  
Conclusions:  Administration of a single 20 mg dose of an aromatase inhibitor at defined times 
of the menstrual cycle did not induce dominant follicle regression or new wave emergence. 
Treatment resulted in continued follicle development, a transient decrease in E2 levels and 
elevated circulating FSH and LH concentrations. The failure of an aromatase inhibitor to 
interrupt dominant follicle development suggests a compensatory mechanism for the acute 
drop in E2 that may involve increased LH and FSH levels.  
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Chapter 1:  General Introduction 
The ovary is the “master” gland of the female reproductive system. In this role, it has 
dual endocrine and exocrine functions that are involved in ovarian follicle growth, ovulation 
(OV) and regression. Menses is the external sign of reproductive cyclicity in humans. The 
traditional model of the human menstrual cycle has two phases, follicular and luteal, based 
on menses. The follicular phase is defined as the stage of the menstrual cycle that begins on 
the first day of menstrual bleeding. During the mid-follicular phase a single “dominant” 
follicle is selected from the recruited cohort for preferential growth and ovulation. The 
selected follicle secretes increasing amounts of estradiol (E2) as it grows to pre-ovulatory 
size. The luteal phase is defined as the stage of the menstrual cycle immediately following 
pre-ovulatory follicle collapse at OV which comprises the formation of the corpus luteum 
(CL), and secretion of progesterone (P4). The luteal phase ends the day prior to the first day 
of the next menses.  
The dynamics of human ovarian function were not well understood prior to the 
introduction of ultrasonography for the detailed study of follicular growth in domestic 
animals. Incorporation of high-resolution ultrasonography in ovarian function research, as 
used in animal models, has allowed the use of OV as the definitive endpoint of defining 
cyclicity. Cyclicity in this sense is termed an inter-ovulatory interval (IOI). This development 
has facilitated comparative research between species. Increasing evidence from 
ultrasonography indicates that multiple waves of antral follicles develop throughout the 
human menstrual cycle. Waves of ovarian follicular development in women are comparable 
to waves documented in several other domestic animal species; however, species differences 
do exist (1).  
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Two or three waves (or cohorts) of follicles develop through out an IOI. The final 
wave in an IOI is ovulatory which is consistent across species. The recruitment of follicles 
into follicular waves is initiated by a rise in the circulating concentration of follicle 
stimulating hormone (FSH). Following the initial rise in FSH, a decline in FSH occurs and 
plays a critical role in dominant follicle selection (2-6). The growth profile of the dominant 
follicle begins to diverge from subordinate follicles in the ovulatory wave at approximately 
10 mm in diameter (3, 4, 7, 8). The dominant follicle produces inhibin B and E2 that 
suppresses the continued growth of subordinate follicles within the same wave and the 
emergence of a new wave through inhibition of pituitary FSH secretion (2, 9-11).  
Basal luteinizing hormone (LH) concentrations induce production of androgens in 
thecal cells that become the substrate for granulosa cells (GC) production of E2 (discussed in 
2.3.2)(12-14). Estradiol production and formation of LH receptors (LHr) on the GC by the 
selected follicle is important in its continued growth. The formation of LHr shifts the 
dominant follicle from FSH to LH receptiveness in the decreasing FSH environment of 
follicle selection (15-17). The dominant follicle in women reaches pre-ovulatory size at 
approximately 22 mm in diameter (8, 18-22). Estradiol production reaches a threshold level 
and peaks providing positive feedback on the hypothalamus/pituitary axis and stimulates the 
pre-ovulatory surge in LH (22, 23). Circulating P4 concentrations begin to rise after the E2 
peak and prior to the LH surge (22, 24-26). Ovulation normally occurs within 24 hours (h) 
of the LH surge reaching its peak concentration (27). Control of follicle growth and OV are 
the focus of fertility therapies and contraception. 
Emergency contraception (EC) was developed empirically with the intent of 
suppressing follicular development, OV, or the ability of a conceptus to implant in the 
uterus (28-30). Modern EC has its roots in 1920s veterinary medicine (31, 32). Estrogenic 
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ovarian extracts were injected intramuscularly in dogs and were shown to interfere with 
pregnancy (31, 32). In the 1970s, research began into the use of combined (estrogen and 
progestin) and progestin-only hormonal EC (31, 32). Combined and progestin-only 
hormonal formulations are the most common EC currently in use; however, the response of 
the ovaries to hormonal EC is unpredictable. Emergency contraception does not inhibit OV 
in the presence of a pre-ovulatory dominant follicle (33-36). The inability of EC to prevent 
OV is problematic given the routine clinical use of the medication. It is therefore necessary 
to re-examine the effects of E2 on follicle growth. 
Aromatase inhibitors (AI) prevent the enzymatic conversion of androgens to 
estrogens and subsequently lower the serum estrogen concentration (37-41). When AI are 
administered before selection as part of fertility treatments, pre-ovulatory sized follicles are 
typically observed 10 to 12 days later (42-49). The inhibition of aromatase prevents estrogen 
production and releases the hypothalamic/pituitary axis from the negative feedback of E2. 
The release results in an increase in FSH secretion and stimulation of ovarian follicle growth 
(44, 45, 49-51). We theorize that if AI were administered after follicle selection the acute E2 
deprivation would initiate atresia of the dominant follicle in the extant wave. Estradiol 
deprivation will release negative feedback on FSH and result in the emergence of a new 
follicular wave without an ovulatory event occurring. We postulate that information 
regarding the mechanisms of follicular suppression and atresia could be used to develop new 
contraceptive technologies. 
The research in this thesis is focused on the physiologic and endocrinologic effects 
of a single, large dose of an AI on ovarian follicle and endometrial development at 
biologically important times of the natural menstrual cycle. We hypothesized that a 
temporary drop in E2 would lead to atresia of the dominant follicle and a shortened interval 
  4 
to menstruation. The literature review presents a synopsis of the available data on ovarian 
folliculogenesis during natural cycles and administration of EC and AI. In addition, the 
principles of ultrasound imaging are reviewed to provide a brief explanation of how the 
convergence of research and clinical techniques was brought to bear on this important 
clinical and physiological question.  
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Chapter 2:  Literature Review 
2.1. Human Female Reproductive Anatomy 
2.1.1. Human Ovarian Anatomy 
The ovaries are a pair of dull white, almond shaped structures that lie on either side 
of the uterus (52). Ovaries develop as indifferent gonadal thickenings along the ventral 
cranial mesonephros (genital ridge) in the lumbar region during embryonic development 
(53). The germ cells migrate from the yolk sac to the genital ridge during week 6 of human 
gestation (53). The ovaries, complete with the complement of germ cells, gradually descend 
to the lesser pelvis in early fetal life until they lie on either side of the uterus. In adults, the 
ovaries are held in place by three ligaments. The ovaries are attached to the posterior-
superior aspect of the broad ligament, postero-inferior to the fallopian tube (52, 54). Ovarian 
and suspensory ligaments hold the ovaries in the peritoneal space near the fimbriated end of 
the fallopian tube (52). 
The size of ovaries change in relation to the stage of follicular development and a 
woman’s age. However, typically normal healthy ovaries do not usually exceed 4 x 3 x 2 
centimetres (cm) (52). A flattened layer of cuboidal cells called the germinal epithelium 
covers the outside of the ovary (54). Immediately beneath the germinal epithelium is the 
tunica albuginea, a condensed, delicate layer of connective tissue (54). The body of the ovary 
is broken into the outer, thick cortex and the inner medulla. The cortex contains follicles and 
corpora lutea at different stages of development and regression (54). The medulla of the 
ovary does not contain any follicles (54). The ovarian blood vessels, lymphatic vessels and 
nerves enter the ovary through the hilum and terminate in the medulla (54).  
The suspensory ligament contains the ovarian vessels and nerves which enter the 
ovary at the hilus (53, 54). The ovarian arteries branch off the abdominal aorta and supply 
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the ovaries, fallopian tubes, labium majus, and the inguinal region (54). Medullary ovarian 
veins emerge as a plexus from each ovarian hilus and then form ovarian veins. The ovarian 
veins branch into the inferior vena cava on the right side and the renal vein on the left. The 
ovarian nerves follow the ovarian arteries to the ovaries and the fallopian tubes (54). The 
ovary only has sympathetic innervation which is supplied by post-ganglionic fibers from the 
ovarian plexus. The sympathetic fibres of the ovarian plexus emerge from the tenth and 
eleventh thoracic spinal segment and are vasoconstrictory.  
2.1.2. Human Uterine Anatomy 
The human uterus is a hollow, pear-shaped, muscular organ lying posterior to the 
urinary bladder and anterior to the rectum (52, 55). The uterus is an average of 7.5 cm in 
length, 2.5 cm in depth and 5 cm in width at its widest point (52). It can be anatomically 
divided into the fundus, body, and cervix (54). The body of the uterus narrows gradually 
from the fundus to the internal os of the cervix (54). The fallopian tubes pass through the 
lateral uterine horns at the top of the uterine body at the level of the fundus, forming a 
connection from each ovary to the uterus. 
The wall of the uterus consists of 3 layers, the perimetrium, myometrium, and 
endometrium. The perimetrium is the outer covering of the uterus (54). The myometrium is 
the thick muscular layer consisting of interlaced longitudinal and circular muscle fibers (54). 
The muscle fibers of the myometrium are arranged in 3 layers: external, middle, and internal 
(54). Blood vessels, lymph vessels, and nerves are intermixed in the muscular layers (54). The 
myometrium also contain spiral arterioles and tube-like uterine glands (54). The spiral 
arterioles and uterine glands extend into the endometrium.  
The endometrium is the inner mucosal layer of the uterus. It is composed of non-
ciliated, columnar epithelium and is broken into the stratum basalis and functionalis (54). 
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The stratum basalis is the subepithelial layer of the endometrium. It is a nucleated, highly 
cellular form of connective tissue capable of further development and contains blood 
vessels, numerous lymphatic spaces, and uterine glands (54). The stratum functionalis is 
subdivided into the stratum spongiosum and stratum compactum layers. The stratum 
functionalis is shed during menstruation and thereafter regenerated by the stratum basalis 
(54). The endometrium thickens during the early follicular phase, under the influence of 
dominant follicle E2 production (56). The endometrium reaches approximately 6-10 mm in 
thickness at the end of the follicular phase and 7-14 mm by the end of the luteal phase (56). 
During the late luteal phase of the menstrual cycle the tall columnar cells become frayed and 
worn at the luminal aspect of the cell (54). Decomposition begins at the luminal edge of the 
endometrium and extends to the deeper stratum spongiosum (54). Blood and the necrotic 
epithelium are shed into the lumen of the uterus and are discharged via the cervix during 
menses.  
The uterus is connected to the surrounding tissue by multiple ligaments. The anterior 
ligament connects the uterus to the bladder at the junction of the cervix and uterine body 
(54). The posterior ligament connects the posterior fornix of the vagina (fibromuscular tube 
connecting the uterus to the external genitalia) to the front of the rectum (54). The broad 
ligaments pass from the sides of the uterus to the lateral walls of the pelvis and also hold the 
fallopian tubes and ovaries in position (54). Two uterine branches of the internal iliac 
arteries, which run through the broad ligaments, are the main arterial supply of the uterus. 
2.2. Human Ovarian Dynamics 
2.2.1. Pre-Antral Follicle Development 
Oogenesis, the formation and development of an ovum, occurs during fetal life. 
Primordial germ cells migrate from the yolk sac to the genital ridge in the developing embryo 
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to form oogonia. The germ cells not exposed to stem cell growth factor and basic fibroblast 
growth factor during transit to the genital ridge from the yolk sac undergo apoptosis (57). In 
the genital ridge the germ cells form oogonial nests and undergo rapid mitosis (58). Somatic 
cells from the mesonephros surround oogonia in the genital ridge to form primordial 
follicles (58). Oocytes in primary follicles cease mitotic divisions and begin meiotic division 
(58). Meiosis of oocytes in primordial follicles arrests in prophase I (58). The population of 
primordial follicles in the ovaries constitutes the ovarian follicular reserve (59, 60). Oogonia 
not enveloped by somatic cells degenerate (57, 58), thus regulating the endowment of the 
ovarian reserve.  
Female mammals are born with their complete complement of oocytes in the 
ovarian reserve (59). Our current understanding is that female mammals are incapable of 
producing more oocytes during reproductive life span (59). The total number of germ cells 
reaches approximately 6,800,000 at 5 months of fetal development the mitotic divisions (59). 
Once the germ cells form primordial follicles and enter the process of meiosis the total 
number of follicles in the ovaries declines progressively. At birth, the population of 
primordial follicles in the ovary is approximately 1,000,000 and at menarche the ovarian 
reserve consists of approximately 270,000 to 470,000 follicles (59). After menarche, there is a 
cyclic depletion of approximately 100 follicles from the ovarian reserve each month(61-64). 
The depletion of follicles from the ovarian reserve results from the entrance of follicles into 
waves (aka cohorts) of development. By menopause the ovarian reserve reaches 100 to 1000 
primordial follicles (62). 
Primordial follicles are comprised of a single layer of somatic cells surrounding 
primary oocytes. Primary oocytes are germ cells arrested in the diplotene stage of meiotic 
prophase I at a size of 32 micrometre (µm) until they are stimulated to resume meiosis 
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during an ovarian cycle (65, 66). The diameter of the oocyte initially increases from 
approximately 30 µm in primary follicles until it reaches approximately 140 µm in diameter 
in pre-ovulatory follicles (67). The morphologic changes associated with each stage of pre-
antral, as well as antral, follicle growth are summarized (Table 2.1). 
Initiation of follicle growth into a pool of growing primordial follicles is a 
multiphasic, continual process regulated by biological molecules that starts during fetal 
development and continues until menopause (66, 67). The phases of follicle growth, 
development and the length of time required to transition from a primordial follicle to an 
ovulatory follicle are illustrated (Figure 2.1).  
The first changes in primordial follicular growth are recognized as the differentiation 
of spindle-shaped GC into cuboidal cells (68) and the formation of the zona pellucida (ZP), 
a protective glycoprotein layer around the oocyte secreted by GC (69). The cuboidal GC 
proliferate and differentiate into cumulus cells surrounding the oocyte and mural cells lining 
the interior aspect of the follicle (70). As preantral follicles increase in diameter, the 
surrounding stromal tissue differentiates into two layers: the theca interna and theca externa 
(Table 2.1)(60). The blood supply in the thecal layer is typically provided by one or two 
arterioles which terminate in a wreath-like pattern of capillaries surrounding the follicle and 
adjacent to the basal lamina (68, 71, 72). At a diameter of 0.2 millimeter (mm) an antrum 
develops within the growing follicles (65, 73). Recruitment of antral follicles into a growing 
phase occurs at regular intervals during the menstrual cycle (3, 74-76). 
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Table 2.1: Classification of follicles and morphological changes associated with stages of 
follicular development in the human ovary (modified from Gougeon, Endocrine Reviews, 
1996)(77). 
 
Phase of Development Stage of Development Morphological Characteristics 
Resting Follicle Primordial Follicle • 35 µm in diameter 
• single layer of flattened GC 
Intermediary Follicle • 38 µm in diameter 
• single layer of flattened and cuboidal GC 
Early Growing Primary Follicle • 46 µm in diameter 
• single layer of cuboidal GC 
• zona pellucida develops 
Secondary Follicle • 77 µm in diameter 
• > 1 layer of cuboidal GC 
• GC express FSH, E2, and androgen receptors 
• Theca interna express Lr 
• Theca interna and externa differentiate 
• follicular vascular and lymphatic systems differentiate 
• 99% of follicles enter atresia 
Pre-Antral Class 1 • 0.1-0.2 mm in diameter 
• 6 x 102 GC 
• 2-cell-2 gonadotropin hormone synthesis  
• no antrum  
• 24% of follicles enter atresia 
Early Antral Class 2 • 0.2-0.4 mm in diameter 
• 3-5 x 103 GC 
• cumulus oophorus develops 
• antrum development commences 
• 35% of follicles enter atresia 
Class 3 • 0.4-0.9 mm in diameter 
• 1.5 x 104 GC 
• small antrum 
• 15% of follicles enter atresia 
Class 4 • 0.9-2.0 mm in diameter 
• 75 x 104 GC 
• medium antrum 
• 24% of follicles enter atresia 
Recruited Class 5 • 2.0-5.0 mm in diameter 
• 37 x 105 GC 
• medium antrum 
• 58% of follicles enter atresia 
Selected Class 6 • 5.0-10.0 mm in diameter 
• 19 x 106 GC 
• medium antrum 
• aromatase activity detected in GC 
• 77% of follicles enter atresia 
Early Pre-Ovulatory Class 7 • 10.0-16.0 mm in diameter 
• 94 x 106 GC 
• large antrum 
Pre-Ovulatory Class 8 • 16.0 - 24 mm in diameter 
• 47-60 x 106 GC 
• ovulation occurs at the end of the phase 
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Figure 2.1: Classification of follicles development stages in the human ovary. Level of 
atresia and number of granulosa cells occurring in class 1 to 8 growing follicles. The 
approximate follicle diameter at the transition between classes and duration of growth at 
each stage are indicated (from Gougeon, Human Reproduction, 1986)(20). 
 
2.2.2. Antral Follicle Development 
Follicle wave patterns of development, first described in domestic animals, (i.e., 
bovine and equine) have been documented in several other mammalian species, including 
women (18, 78-85). Comparative studies have shown similarities in ovarian follicular wave 
dynamics between monovular domestic farm animals and humans (86-88). Follicular waves 
are defined as the synchronous growth of cohorts of follicles from which one or more 
follicles may be selected for preferential growth (89). The follicles recruited into the wave are 
similar, but not identical, diameters (3, 81, 88, 90). Most women exhibit 2 waves of follicle 
growth (68%) while the remaining 32% exhibit 3 waves of follicle growth (18). 
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 Antral follicular development can be characterized over an inter-ovulatory interval 
(IOI; i.e., from OV to OV) or across the menstrual cycle  (i.e, from menses to menses; an 
inter-menstrual interval; IMI). The advantage of evaluating follicular dynamics over an IOI is 
that it allows characterization of ovarian function across the entire ovarian cycles, regardless 
of uterine function. Each IOI (or corresponding menstrual cycle) is comprised of 2 or 3 
waves of follicle development.  (Figure 2.2a-f)(1, 3, 18, 90). Emergence of each follicular 
wave during the IOI in women is preceded by an elevation in circulating FSH (3), consistent 
with previous reports in domestic animals (2, 3, 91, 92). Major waves are defined as those in 
which a dominant follicle is selected at 10 mm in diameter to continue growth while all other 
follicles undergo atresia (3, 80). In minor waves selection of a dominant follicle is not 
manifest and no follicles grow > 10 mm in diameter (3, 80). The final wave of the IOI is a 
major ovulatory wave, while all preceding waves, major or minor, are anovulatory (3, 86). 
The earlier wave emergence, selection, and pre-ovulatory surge in 2 wave cycles leads to a 
shorter average IOI and corresponding menstrual cycle compared to 3 wave cycles (3).  
2.2.2.1. Follicluar Dynamics 
The growth of the antral follicle waves consists of up to 4 stages, depending on 
whether the wave is major or minor, ovulatory or anovulatory. The 4 stages are: 1) wave 
emergence (also referred to as recruitment of the follicular cohort); 2) selection 3) pre-
ovulatory follicle growth; and, 4) OV (66). Each of these important physiologic events is 
discussed below.  
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Figure 2.2 a-c: Morphologic and endocrinologic changes associated with 2 waves of follicle 
development during the menstrual cycle. Data encompass one complete menstrual cycle and 
one complete inter-ovulatory interval. Vertical lines indicate the days of wave emergence, 
follicles are shown in pink, and the corpus luteum is in yellow. Major anovulatory waves are 
ghosted due to detection in some but not all women prior to the ovulatory wave. (From 
Baerwald, et. al, Human Reproduction Update, 2012)(1). 
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Figure 2.2 d-f: Morphologic and endocrinologic changes associated with 3 waves of follicle 
development during the menstrual cycle. Data encompass one complete menstrual cycle and 
one complete inter-ovulatory interval. Vertical lines indicate the days of wave emergence, 
follicles are shown in pink, and the corpus luteum is in yellow. Major anovulatory waves are 
ghosted due to detection in some but not all women prior to the ovulatory wave. (From 
Baerwald, et. al, Human Reproduction Update, 2012)(1). 
 
2.2.2.1.1. Wave Emergence 
A cohort of 3 to 20 antral follicles between 2.0-5.0 mm in diameter is recruited to 
grow at regular intervals over the menstrual cycle (3, 8, 68, 93). Emergence of the follicular 
wave is preceded by an elevation in circulating FSH (3). A rise in FSH levels 10-30% above 
basal levels is required for wave emergence (67, 76, 77, 94-97). Anti-Mullerian Hormone 
(AMH), secreted by GC of growing follicles, is involved in the regulation of antral follicle 
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sensitivity to FSH during recruitment in humans (98). The antral follicle responds to 
increasing FSH concentrations by an increased rate of GC mitosis and by increased antral 
volume via aminoglycan production (77). The rise in FSH at the time of wave emergence 
induces expression of genes for FSH receptors (FSHr), the insulin-like growth factor (IGF) 
system, activin and the aromatase enzyme which regulate follicle growth beyond emergence 
(8, 77, 99-101). The number and health of the cohort of follicles that emerge in response to 
FSH is reflected in the rise in inhibin B (102). The GC of all antral follicles of the recruited 
cohort produce inhibin B. Inhibin B production peaks on the fifth day of the follicular phase 
(102). Research is required to further our understanding of the physiologic mechanisms 
underlying follicle wave emergence (1, 3).  
2.2.2.1.2. Dominant Follicle Selection 
Selection refers to the preferential growth of one follicle from a recruited cohort of 
antral follicles (3, 4, 7, 8, 20, 25, 74). Follicle selection always occurs during the ovulatory 
wave in the early to mid-follicular phase of the menstrual cycle (3, 7, 18).  However, selection 
can occur following emergence in any follicular wave. 
The selected follicle is called the “dominant follicle”, while all other follicles of the 
wave are called “subordinate”. At the time of selection, the growth profile of a selected 
follicle begins to diverge. Specifically, the dominant follicle continues to grow while the 
subordinate follicles enter a static phase or undergo atresia (7, 9). The divergence in growth 
trajectories occurs when the dominant follicle reaches a diameter of approximately 10 mm 
on day 6 to 9 of the follicular phase in women (3, 4, 7, 8). During the growth phase of the 
dominant follicle the emergence of the next follicular wave is suppressed (2, 9). It has been 
suggested that decreasing FSH in concert with increasing E2 secretion are the primary 
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regulators of selection, regression and timing of emergence (2, 9). However, the complete 
mechanism of selection has not been fully elucidated (3, 77). 
The interval of time that FSH is elevated above the threshold (rather than the 
magnitude of the rise in FSH) has been implicated in determining the number of follicles 
from the cohortselected for preferential growth (103, 104). The interval that FSH 
concentrations remain above the basal threshold levels is called the ‘FSH window’ (12, 103, 
105-108). The duration of the FSH window aids in explaining the number of follicles that 
are selected to continue growing (12, 103, 105-108). In natural menstrual cycles, the duration 
of the FSH window is short such that typically only a single dominant follicle is selected. The 
decline in FSH occurring at the time of selection is critical the mechanism underlying the 
dominant between the growth of the dominant follicle and subordinate follicles (2, 9). 
It has been postulated that the dominant follicle has an early size advantage (109, 
110). The future dominant follicle may contain more GC and FSHr which increase the 
dominant follicle’s sensitivity to FSH (103). At selection the declining FSH environment 
leads the subordinate follicles to undergo atresia (3, 4, 16). It is thought that the smallest 
follicles in the cohort are least sensitive to FSH and undergo atresia first, followed by the 
regression of progressively larger follicles in the wave until only the dominant follicle 
remains (9, 110).  
Until follicle selection, pre-antral follicles of the recruited cohort continue to secrete 
AMH (111). Anti-Mullerian hormone production decreases in association with a rise in 
aromatase expression and E2 synthesis in the GC (112). The expression of aromatase 
increases in 6-8 mm diameter follicles (4, 22, 25, 113-119). The dominant follicle produces 
more E2 that the other follicles in the cohort prior to selection. The aromatase enzyme 
(discussed in section 2.3.2) is not fully functional until the follicular diameter exceeds 10 mm 
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(77). Production of androgens in the thecal cells by LH-induction provides the substrate for 
E2 (12-14). The follicular fluid of the dominant follicle has a higher estrogen to androgen 
ratio, while atretic follicles exhibit a greater androgen to estrogen ratio (77, 118). The E2 
production of the dominant follicle contributes to the negative feedback on pituitary FSH 
secretion and the decrease in circulating FSH (120). Formation of LH receptors of the GC 
of the dominant follicle following E2 secretion allows the dominant follicle to become more 
responsive to LH and less dependent on FSH following selection (15, 16, 121).  
Inhibins A and B play critical roles in control of folliculogenesisPituitary secretion of 
FSH declines in concert with increasing inhibin B secretion in the early to mid-follicular 
phase (122-124). Increasing inhibin B is one component in inhibiting pituitary FSH 
secretion. Inhibin B production peaks at a follicle diameter of 9-10 mm (125) when inhibin 
A production increases (126). The production of inhibin A by the GC of the selected follicle 
increases androgen production by the thecal cells (127). An orderly transition from an 
inhibin B/activin environment to an inhibin A/follstatin environment has been proposed to 
be critical to the development of a dominant follicle in women (126, 128, 129). 
The decreased dependency of the dominant follicle on FSH may also be the result of 
the acquisition of LHr by GC (15). Mural granulosa cells adjacent to the basal lamina, which 
are in close proximity to the theca interna vascular supply, express more LHr (93). Both 
FSHr and LHr are coupled to the cAMP signaling system. Thus, similar signal transduction 
responses occur with the binding of FSH and LH to their respective receptors (101). Serum 
LH concentration begins to increase in the mid-follicular phase (16, 130). In the presence of 
declining FSH and increasing LH concentrations, dominant follicle growth continues as a 
result of the additive effect of increased FSHr and LHr (131). 
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The dominant follicle is saved from atresia, in part, through increased IGF-I and II 
production and bioavailability (132, 133). The IGF system stimulates aromatase activity and 
estradiol production in the GC, while simultaneously promoting androgen production in 
thecal cells surrounding the growing dominant follicle (132, 133). The bioavailability of IGF-
I and II is not increased in subordinate follicles. IGF is sequestered by IGF binding protein-
4 (IGFBP-4) inhibiting GC and theca steroidogenesis and ensuring atresia (132, 134-136).  
Continued growth of the dominant follicle is affected by a decrease in FSH and 
AMH, changes in the production of inhibin B to inhibin A, and an increase in aromatization 
of androgens to E2 with the assistance of IGF-I and II. The follicle has developed a larger 
antrum and a large compliment of GC with an increased number of FSHr and LHr. The 
hormonal milieu allows the selected follicle to continue growing and attain pre-ovulatory 
status. 
2.2.2.1.3. Pre-Ovulatory Follicle Growth 
The process of dominant follicle maturation proceeds through the final two stages of 
follicle development, early pre-ovulatory and pre-ovulatory (Table 2.1)(77). The dominant 
follicle in an ovulatory wave increases from 10-24 mm on average, over the final 8 to 10 days 
of growth (66). The growth of the dominant follicle is associated with mitosis of GC and the 
accumulation of antral fluid (20). Growth occurs through proliferation of granulosa and 
thecal cells and the accumulation of antral fluid (20). By day 9 of a typical 16 day follicular 
phase, the density of the vasculature of the theca interna within the dominant follicle is twice 
that of all other follicles in the ovary; the vasculature facilitates preferential delivery of 
gonadotropins to the GC LHr (137).  
The estrogen to androgen ratio increases as aromatase expression increases and 
estrogen production continues (77). Increased levels of inhibin A in CG stimulate thecal 
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androgen production. Elevated expression of IGF-II messenger ribonucleic acid (mRNA) in 
the GC stimulate aromatase enzyme activity. The venous effluent of the ovary containing the 
pre-ovulatory follicle has elevated levels of E2. There is a correlation between increasing 
concentrations of serum E2 and the size of the pre-ovulatory follicle (4, 138). The rate of 
granulosa cell mitosis declines as the GC and their nuclei increase in diameter at the end of 
pre-ovulatory follicle development (22). At this stage the basement membrane becomes less 
visible. The thecal layer continues to undergo hypertrophy and increased vascularization 
until ovulation occurs (66).  
The dominant follicle is considered mature upon reaching pre-ovulatory size (16-28 
mm). Ovulation occurs in response to a surge of LH at about day 14 to 16 of the follicular 
phase (77). A pre-ovulatory follicle will regress if a LH surge does not occur (77).  
2.2.2.1.4. Ovulation 
The elevation of E2 in the late follicular phase triggers the pituitary release of LH 
(139). The rapid release of LH initiates the process of OV which involves complex 
biochemical, morphological, and physiologic changes in and around the 16-28 mm dominant 
follicle (3, 18, 22, 77, 140). The changes continue until the follicle wall ruptures and the 
oocyte is released. The pre-ovulatory follicle takes approximately 36 to 38 h to 
rupture/ovulate following the onset of the LH surge in humans (140). The biochemical and 
physiologic changes associated with OV are not fully elucidated (140). 
The regulatory systems induced by the LH surge act synergistically to induce changes 
in the vasculature and extracellular matrix (140, 141). The extracellular matrix is stimulated to 
degrade by the LH surge. The LH surge stimulates the granulosa and theca intera cells to 
produce plasminogen activator (141-143). Plasminogen activator initiates the conversion of 
plasminogen to plasmin in follicular fluid. The plasmin generates collagenases which digest 
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the dense collagen layer of the tunica albuginea and the theca externa at the apex of the 
follicular wall (142, 144). Blood vessels of the theca interna invade the granulosa layer as the 
basal lamina breaks down immediately before OV (145).  
Initiation of P4 synthesis in the GC is induced by increased numbers of LHr and 
tonic LH secretion (146, 147). The LH surge suppresses GC mitosis and simultaneously 
stimulates formation of large lacunae within the GC. Changes in the GC following the LH 
surge results in a decrease in follicular fluid estrogen and androgen concentrations and 
increased production of P4, prostaglandin E2 (PGE2; a vasodilator), and prostaglandin F2α 
(PGF2α; a vasoconstrictor) before follicle rupture (146-149). However, the exact roles of P4, 
PGE2 and PGF2α in follicle rupture remain poorly elucidated.  
The pre-ovulatory LH surge also stimulates changes in the oocyte. The oocyte is 
stimulated to complete the first meiotic division and becomes arrested at prophase II as a 
secondary oocyte (20, 150). To stimulate the oocyte to complete the first meiotic division, 
the LH surge must reach a threshold concentration and be sustained for 14 to 27 h (141, 
149, 150). The LH surge suppresses the action of oocyte maturation inhibitor (141, 149, 
150). Final maturation of the oocyte and completion of meiosis will only be completed after 
fertilization (141, 149).  
The final stages of the ovulatory process include expansion, loose reorganization, 
and increased vascularization of the follicular wall (151, 152). The follicle wall thins at the 
apex and thickens at the deep internal portion approximately 3 h prior to ovulation (151, 
152). The apex is a small portion of the follicle wall digested by enzymes until the point 
where the tensile strength of the wall is no longer able to sustain the intra-follicular osmotic 
pressure (15-20 mm Hg)(148). A stigma forms at the follicular apex approximately 15 to 20 
minutes (min) before follicle rupture due to thinning of the layers of collagen and 
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degradation of connective tissue elements (59, 152). The surface epithelium becomes 
necrotic and sloughs off at the apex of the follicle immediately before follicle rupture (153). 
The oocyte-cumulus complex, that is the oocyte surrounded by cumulus oophorus cells, 
floats freely in the follicular fluid just prior to OV. The follicular fluid and oocyte-cumulus 
complex evacuate the antral cavity when the stigma of the ovulatory follicle wall ruptures 
(144). Rupture of the follicle occurs at the stigma and within 15 seconds (sec) approximately 
50% of the follicular fluid is released. The time required for complete evacuation of follicular 
fluid ranges from 6 sec to 18 min (152).   
One of 3 structures are seen in the event of ovulatory failure: simple anovulatory 
follicular cysts, hemorrhagic anovulatory follicles (HAF), and luteinized unruptured follicles 
(LUF). Anovulatory follicular cysts may regress, remain static for several days and then 
regress, or grow past the typical pre-ovulatory diameter (> 25 mm) and persist prior to 
eventual regression (55, 151). Hemorrhagic anovulatory follicles are characterized by internal 
hemorrhage and fibrin network formation within the antrum (55). Luteinized unruptured 
follicles are characterized by a thickened (i.e., luteinized; discussed in section 2.2.2.2) 
follicular wall without release of the follicular fluid and the oocyte-cumulus complex. 
Luteinized unruptured follicles can hemorrhage internally. Regression of LUF occurs over a 
time period similar to that associated with normal CL regression (55).  
2.2.2.2. Luteal Dynamics 
The luteal phase begins immediately after follicle rupture with the formation of the 
CL. Luteinization is the process of CL formation through structural and functional 
remodeling of the theca and granulosa cell. The LHr on the cellular surface of transforming 
theca and granulosa cells allow for normal CL function(154, 155). Tonic secretion of low 
circulating levels of LH occurs during the early luteal phase.  
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Two parallel, but distinct events occur during initiation of luteinization. First, an 
extensive capillary network forms in the granulosa layer of the follicle following the 
disruption of the basement membrane (154).  Second, the theca interna and mural granulosa 
cells transform into 2 populations of steroidogenically active lutein tissue (154).  The former 
theca interna becomes small-luteal or paraluteal cells while the GC become large-luteal or 
luteal cells (154). Little is known about the mechanism of thecal cell remodeling; however, 
the transformation of GC into luteal tissue involves cellular hypertrophy with an increase in 
the nuclear to cytoplasmic volume ratio (155). 
The two types of luteal cells differ in size, location, function, and regulation by 
endocrine and local factors (154). Paraluteal cells are less than 20 µm diameter and luteal 
cells are greater than 22 µm diameter (154). Paraluteal cells are located around the outer 
periphery and in the peripheral invaginations of the CL (154). Luteal cells are found in the 
central portion of CL tissue (154). Luteinizing theca and granulosa cells fill the antrum of the 
former follicle (154, 156). Some corpora lutea release their follicular fluid, then refill to form 
a ‘cystic cavity’ and do not completely involute (21, 156-159). Corpus hemorrhagicum (CH) 
results when a hemorrhage occurs within a developing luteal gland. A CH occurs in 
approximately 60% of ovulations (160). The structure of the CL is typically visible by 4 to 6 
days following OV (154).  
The paraluteal and luteal cells of the CL synthesize many hormones, including but 
not limited to P4, E2 and relaxin. Luteal cells secrete 10 to 20 times more P4 than paraluteal 
cells (154). The principal endocrine change during luteinization is the production of P4 (155). 
Luteinization increases the cellular receptors for low density lipoprotein (LDL). The 
receptors facilitate the intracellular transport of cholesterol for P4 production (155).  
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The CL also contains several types of non-luteal cells.  Endothelial cells are the most 
important type of non-luteal cell found. Endothelial cells are involved in luteal gland vascular 
development (154). The high number of endothelial cells found in the developing luteal 
gland along with the paraluteal and luteal cells correlate with increasing blood flow to the CL 
during the first 6 days of the luteal phase (161). The luteinizing follicle produces angiogenic 
factors, including vascular endothelial growth factor (VEGF) and vascular permeability 
factor (VPF). Angeogenic factors diffuse through the disrupted basement membrane and 
facilitate the formation of an extensive capillary network within the developing CL (155). 
Peak vascularity in the CL occurs 7 days after ovulation, which is the approximate day of 
maximum P4 secretion (10-18 nanograms per millilitre; ng/mL) in a non-conception 
menstrual cycle (159, 162). The CL persists in the ovary in the presence of embryonic human 
chorionic gonadotropin (hCG) secretion which maintains P4 secretion by the CL and 
prevents regression of the CL (163-166). Regression of the CL is referred to as luteolysis.  
If pregnancy is not established, the CL begins to regress approximately 7 days after 
OV (165, 167). A decline in both the amplitude and frequency of LH pulses occurs in the 
mid-luteal phase. Declines in circulating estrogen and PGF2α, are involved in luteolysis. 
During luteolysis there is a decrease in the vascular supply and a decrease in cell size of the 
CL (167). Ultimately there is a loss in P4 production (159).  
Changes in the redox state of the luteal cells appears to regulate the lifespan of the 
CL (168, 169). The regulation of reactive oxygen species in the CL is managed in concert by 
PGF2α and hCG (168-171). Human chorionic gonadotrophin directly suppresses the 
occurrence of apoptosis in the CL through prevention of oxidative stress while PGF2α 
interaction with its receptor causes generation of free radical oxygen species and prolonged 
oxidative stress (168, 170). In domestic animals, PGF2α is produced in the uterus; however, 
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in primates PGF2α is produced by the CL (154). The regulation and action of PGF2α in 
humans also may be influenced by its balance with PGE2 which is a promoter of early luteal 
function (154).  
The ratio of paraluteal and luteal cells changes as the lifespan of the CL progresses 
due to apoptosis and autophagocytosis (154). The alterations in CL cell ratios lead to gradual 
involution of the structure in the ovary (172). By the end of the menstrual cycle, involution 
of the luteal gland culminates in a small structure composed primarily of connective tissue 
called the corpus albicans (white body; CA)(172). The corpus albicans persists on the ovarian 
surface as a small white scar for several menstrual cycles (167). 
2.3. Estradiol 
2.3.1. Sex Steroid Hormone Pathway 
The principal biosynthetic pathways for production of sex steroid hormones are 
summarized and are not unique to any specific tissue site (Figure 2.3). Sex steroid hormones 
are located at the end of the cholesterol steroidogenesis pathway. The major circulating form 
of steroidogenic cholesterol in humans is LDL (173). Delivery of LDL to the ovary allows 
for synthesis of androgens by thecal cells and aromatization of androgens to estrogen via the 
aromatase enzyme. 
2.3.1.1. Estradiol Synthesis in the Ovary 
The synthesis of E2 in growing follicles occurs via interactions between GC and cells 
of the theca interna. Estradiol synthesis influenced by LH and FSH levels, the number of 
LHr and FSHr and the availability of precursor substrates. Studies characterizing E2 
synthesis in the ovary have been completed in the bovine model and are similar to human 
ovarian steroidogenesis (174, 175).  
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The vascular anatomy of the follicles in the ovary determine the degree to which 
circulating LDL serves as steroid precursors and the cells that are able to utilize LDL (173). 
Thecal cells of each follicle receive blood from the rich vascular supply of the ovary and are 
therefore in a position to utilize the circulating LDL. The basement membrane between the 
theca and granulosa layers of the follicle isolates the GC from direct contact with the ovarian 
blood supply (Figure 2.4)(173). 
LH stimulates thecal cells to convert LDL to androgens (65, 77, 173). The availability 
of androgens produced by thecal cells controls E2 secretion by GC (174). Androgens then 
cross the basement membrane into the GC where aromatase converts the androgens to 
estrogens (65, 77). Conversion of the androgens to estrogens involves a three-step reaction 
with aromatase in the granulosa cell mitochondrial agrandular endoplasmic reticulum (173, 
176, 177). The final step in the production of estrogens is the aromatization of the androgen 
A ring (40, 178-181). The estrogens are subsequently released into the follicular fluid, intra-
follicular space and systemic circulation (65, 77).  
2.3.2. Aromatase Enzyme 
The aromatase enzyme, or estrogen synthetase, is a microsomal member of the 
cytochrome P450 heme-protein containing enzyme complex superfamily (51, 181-184). 
Aromatase is responsible for catalyzing the conversion of androgens to estrogens is 
conserved across chordate species, sexes, and tissue types. In females, aromatase activity has 
been identified in the ovaries, placenta, brain, adipose tissue, muscle, liver, breast tissue, and 
malignant breast tumors (51, 180-185).  
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Figure 2.3: The principal biosynthetic pathways in the production of progestins, androgens, 
and estrogens from circulating vascular cholesterol. Cholesterol is metabolized into 
estrogens through 5 sequential enzyme systems. (Modified from Richfield, 2008). 
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Figure 2.4: The 2-cell-2-gonadotrophin theory of estradiol production in the mammalian 
ovary (Modified from Adashi, Chapter 2, Reproductive Endocrinology, Surgery, and 
Technology, 1996)(65). 
 
Transcription of aromatase in the GC of the ovary is induced by FSH (186). The 
aromatase enzyme is a 503 amino acid (aa) protein with a molecular weight of 55 kiloDalton 
(kDa)(178, 181, 187). The folding process produces 12 helices that are coded from A-L 
(188). A heme-containing protoporphyrin is located between helices I and L. The heme 
group is linked to the protein through a covalent bond with the sulfur atom of a cysteine aa 
and by a network of hydrogen bonds with positively charged aa (188). Substrate recognition 
occurs between helices B, C, F and G near the center of the folded enzyme (188). 
Interaction of substrates with the enzyme’s active site occurs through a coordination bond 
with the heme group, hydrophobic bonding to approximately 10 aa and hydrogen bonding 
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to approximately 6 aa (188). Aromatase has the capacity to bind all 3 natural carbon 19 
androgens (189) and catalyzes a 3 step reaction that rearranges the androgen A ring to an 
aromatic structure (173, 176, 177). 
Aromatase binds to, and saturates, areas of the endoplasmic reticulum of cells in 
estrogen producing tissues tissues (40, 178-181, 189, 190). Reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) readily binds to membranes of the endoplasmic reticulum 
saturated with aromatase. Heterodimerization of aromatase with NADPH facilitates the 
conversion of androgens to estrogens (190). Following estrogen synthesis, nicotinamide 
adenine dinucleotide phosphate (NADP+) is released and a new NADPH heterodimerizes 
with the aromatase enzyme. 
2.4. Aromatase Inhibitors 
2.4.1. Development of Aromatase Inhibitors 
Aromatase inhibitors are compounds that act as false substrates for the aromatase 
enzyme through competitive binding with androgens for the heme moiety of aromatase 
(182-184). Aromatase inhibitors are classified as either steroidal or non-steroidal.  Steroidal 
aromatase inhibitors are also named suicide inhibitors, type I inhibitors, mechanism-based 
inactivators, and aromatase inactivators (181-184, 191). Non-steroidal inhibitors are also 
called type II inhibitors and competitive inhibitors (181-183). Steroidal and non-steroidal 
inhibitor development started in the 1960s. Three developmental generations have occurred 
to improve the safety profile, increase potency and increase selectivity for aromatase binding 
(192). 
2.4.1.1. Letrozole 
Letrozole (Femara®, Novarts) is an achiral non-steroidal, third generation inhibitor 
of aromatase derived from triazole (Figure 2.5). Letrozole is completely absorbed after oral 
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administration and has a biological elimination half-life of 48 h (51, 182-184). An oral dose 
as low as 0.25 milligrams (mg) per day induced maximal plasma estrogen suppression in 
healthy women and breast cancer patients. A 98% decrease in circulating E2 to 0.06 picomol 
per litre (pmol/L) was reported following letrozole administration (181). Side effects 
reported by trial subjects were rare but included gastrointestinal disturbances, asthenia, hot 
flashes, headache, and back pain (51, 183, 184).  
 
Figure 2.5: Chemical structure of letrozole. The base structure is a triazole group that 
competitively binds to the heme group of the aromatase enzyme. (from Lang, et. al, J Steroid 
Biochem Mol Biol, 1993)(193). 
 
2.4.2. Use of Aromatase Inhibitors in Fertility Treatments 
Commercially available aromatase inhibitors are registered solely for treatment of 
hormone-dependent breast cancer in post-menopausal women (194, 195). Letrozole is 
classified as embryotoxic and is contraindicated for pre-menopausal women who have 
ovaries in situ and any women attempting to become pregnant (194, 195). An increase in 
circulating concentrations of FSH and LH following letrozole treatment in mature female 
rats and bonnet monkeys was associated with the development of multiple normal pre-
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ovulatory follicles (196). The rationale for AI use as a fertility therapy in humans was to 
remove circulating E2 and release the hypothalamic/pituitary axis from the negative feedback 
of E2 (182, 197). The release of negative feedback results in an increase in FSH secretion and 
stimulation of ovarian follicle growth (44, 45, 49-51). There are numerous reports of 
aromatase inhibitor use in the treatment of infertility, for women undergoing ovarian 
stimulation, intrauterine insemination and timed intercourse (106, 198-205). Aromatase 
inhibitors have been used before follicle selection for ovarian stimulation as a large single 
dose or low dose 5 day regimen (43, 48-50, 182, 196, 200-202, 206-211). Aromatase 
inhibitors also have been used in combination with FSH to decrease the dose of 
gonadotrophins required to achieve an acceptable stimulatory response (45, 47, 48, 199, 205, 
212-216). Use of AI in fertility therapy has been successful in achieving pregnancy; however, 
concerns still remain regarding fetal safety following AI use.  
A retrospective study presented in 2005 by Biljan challenged the safety of letrozole 
use in infertility treatment. Increased risks of bone malformations and cardiac anomalies 
were correlated with the use of letrozole in infertility treatment (217). However, the 
increased risks of congenital anomalies following letrozole use (previously reported) were 
not higher than the reported 1.3 fold increased risk of congenital anomalies for babies born 
after all assisted reproductive therapies above the baseline rate of anomalies (2-4%) without 
treatment (218, 219). Limitations in study design have led to questions regarding the 
scientific credibility of the Biljan study. Teratogenic effects on fetal development were not 
observed in a more recent retrospective study on the use of letrozole in fertility therapies 
(220). A prospective trial to evaluate pregnancy outcomes after ovarian stimulation with AI 
further confirmed the safety of AI as a tool for management of infertility in women (221). 
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2.5. Emergency Contraception 
Emergency, or post-coital, contraception is often called “the morning-after pill”. 
Emergency contraception is intended to prevent pregnancy when used 72 to 120 h after 
unprotected intercourse or following failure of other forms of contraception (222-226). 
Emergency contraception is rooted in 1920s veterinary medicine practice where estrogenic 
ovarian extracts were injected intramuscularly to prevent conception following unintentional 
breedings (31, 32). The first published cases of estrogen injections for EC in humans were 
described in the mid-1960s (31, 32). In an effort to increase the efficacy of pregnancy 
prevention, the use of combined estrogen/progestin and progestin only hormonal 
combinations as EC was investigated in the 1970s.  
Two hormonal EC regimens and one non-hormonal EC method are currently 
available in Canada (227). Plan BTM is a hormonal emergency contraceptive consisting of 2 
oral doses of 0.75 mg levonorgestrel (LNG) taken simultaneously (227, 228). The second 
hormonal method is the Yuzpe method, off label use of oral contraception. Treatment with 
the Yuzpe method consists of 2 doses of a combination of 0.1 mg ethinyl estradiol (EE) and 
0.5 mg LNG taken 12 h apart (227, 229-231). The non-hormonal method includes the 
insertion of a copper intrauterine contraceptive device (IUCD) prior to the time an embryo 
would be transported from the site of conception in the oviduct to the uterine cavity. A new 
hormonal method, ulipristal acetate, was approved for use in August 2010 by the United 
States Federal Drug Administration (FDA)(232). Ulipristal acetate, EllaTM, is a selective 
progesterone-receptor modulator and is designed to be taken as a single 30 mg oral tablet 
within 120 h of unprotected intercourse or barrier contraceptive failure (232).  
The mechanisms of action of hormonal emergency contraceptives remain poorly 
elucidated. The two main hypotheses to explain their contraceptive action include 
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prevention of fertilization and/or prevent implantation. Prevention of fertilization may 
occur by preventing follicular development, and/or ovulation or by affecting sperm function 
and/or sperm migration through the female reproductive tract (30, 233-236). Prevention of 
implantation is thought to involve an alteration in endometrial receptivity and/or luteal 
function (30, 234-236). 
2.5.1. Ovarian and Endometrial Function following use of EC 
Follicular development, ovulation, and gonadotropin response to the administration 
of EC have been studied (28-30, 32, 229, 235-246). Emergency contraceptives are effective 
at preventing pregnancy when administered at follicle diameters < 12 mm (35, 236). 
Pregnancy is less likely to occur following unprotected intercourse at this time regardless of 
whether or not emergency contraceptives are administered because OV is unlikely to be 
imminent (35, 236). A delay or blunting of a LH surge has been observed following EC 
administration in the presence of a dominant follicle < 17 mm in diameter (28, 30, 35, 234, 
246); no effects were observed at a follicle diameter of 18 mm (28, 30, 35, 234, 236, 246). 
Hormonal EC also have the potential to interfere with the formation or endocrine function 
of the CL. This mechanism of action is dependent upon the time of the LH peak and EC 
regimen used (242, 243). 
Endometrial receptivity following EC use has also been studied. Use of LNG 
contraceptives before a LH surge did not affect the morphology of the endometrium or any 
known markers of receptivity at the expected time of implantation (243, 247, 248). In 
contrast, EC use in the early luteal phase has been shown to cause alterations to endometrial 
function at the cellular level (249-251). Changes to the normal IMI of participants were 
observed after a single treatment with LNG (252). The change in IMI length was dependent 
on the timing of EC initiation (252). 
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2.6. Ultrasonographic Imaging in Female Reproductive Physiology 
2.6.1. Overview of Ultrasound Imaging 
The study of ovarian follicular development was revolutionized by the development 
of non-invasive ultrasonographic imaging. Ultrasonography provided an atraumatic and non-
invasive tool with which to observe serial changes in reproductive function not possible with 
endocrinologic or histologic evaluation (151, 152). Serial ultrasonography can be used to 
increase our understanding of reproductive physiology, pathophysiology and improve the 
clinical diagnosis of ovarian and uterine disease (55, 253).  
Medical diagnostic ultrasonography uses high frequency sound waves (above 20 
kHz) to generate images of stationary and moving tissues in the body (253-256). Briefly, 
ultrasound systems are composed of a transducer, computer processor, and monitor. The 
transducer contains piezoelectric crystals which expand and contract to emit sound waves. 
Tissues in the body either reflect or propagate the acoustic pressure waves depending on the 
acoustic impedance of the tissue. Changes in tissue density at tissue interfaces determine the 
echotexture (proportion of the acoustic pressure wave reflected, absorbed or scattered) of 
the tissue which in turn determines the amplitude of the returning ultrasound wave. Dense 
structures reflect most of the acoustic pressure waves and appear hyper-echoic, while fluid-
filled structures propagate the waves and appear hypoechoic (52). The reflected acoustic 
pressure waves cause the piezoelectric crystal in the transducer to compress and 
subsequently generate an electrical signal. The electrical signals are amplified and then stored 
as binary digits in a digital scan converter. The binary information is stored in a matrix of 
picture elements (pixel) which are then displayed on a monitor.  
Each pixel represents a discrete tissue reflector. The go-return time of the echo 
determines the depth of the tissue reflecting the sound wave. The deeper the tissue, the 
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weaker the amplitude of the returning echo. The brightness of a pixel is related to the 
amplitude of the reflected signal and is displayed as one of 256 shades of grey (hypoechoic, 
black = 0 and hyper-echoic, white = 255)(255). Balancing the brightness of the echoes that 
originate from distal reflectors and proximal reflectors in the displayed image is done 
through application of internal gain controls. Numerous acoustic pressure beams are focused 
to increase lateral resolution, while axial resolution is optimized through increased 
ultrasound frequency (256). 
Received echoes can be displayed in different modes. Amplitude mode (A-mode) is 
useful for accurate transducer-to-tissue distance measurements by mapping the signal 
amplitude versus reflection distance of the returning echo signal (253, 256). Brightness mode 
(B-mode) displays the received echo signals as intensity modulated dots on the screen (253, 
256). Motion mode (M-mode) is the sweeping of the B-mode trace across the screen while 
holding the ultrasound beam stationary. M-mode displays motion of tissues in the track of 
the sound waves (253, 256). 
In research and clinical examinations of the female pelvis, transvaginal 
ultrasonography (TVS) is preferred over transabdominal ultrasonography due to the 
increased resolution (257, 258). The ovaries and uterus are easily visualized using B-mode 
TVS due to the close proximity of the organs to the transducer. Transvaginal 
ultrasonography may be utilized to monitor ovarian and endometrial changes during natural 
menstrual cycles, infertility treatments, post menopause, hormonal contraceptive use, and 
research (52). Clinicians also use TVS to aid in invasive procedures, detect and monitor early 
pregnancy and assess reproductive tissues for anomalies (55, 259). Additionally, TVS is used 
for elucidating the effects of treatments on ovarian and uterine function. 
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2.6.2. Ultrasonographic Image Characteristics of the Ovary 
Ovarian tissue images are characterized by a coarse low-level echo pattern (52). 
Interspersed within the low level echoes comprising the ovarian stroma are hypo-echoic 
spheres which represent ovarian follicles (52). Follicles as small as 2 mm in diameter can be 
detected (Figure 2.6). The detection of dominant follicles occurs simultaneous to a rise in 
plasma E2 (4). Mature pre-ovulatory follicles measure 18-24 mm in diameter (52). Changes in 
pre-ovulatory follicle morphology associated with impending OV (discussed in 2.2.1.4) 
appear as decreased echogenicity of the follicular wall (52, 151). Following OV, the 
developing CL can be observed at the location of the former pre-ovulatory follicle 
(described in 2.2.2; Figure 2.6)(152, 167, 260). The point of follicular rupture can be 
observed with ultrasonography for up to a week following OV (55). Ultrasonographic 
characteristics of the CL are highly variable due to the macroscopic changes that occur 
during luteal formation. The outer surface of the CL has a hyperechoic echotexture 
compared to the relative hypoechoic echotexture of the central portion of cystic CL (167).  
The ultrasonographic echotextural characteristics of the 3 types of ovulatory failure 
(discussed in 2.2.1.4.1) can be used to assess if anovulation has occurred. Anovulatory 
follicles have predominantly thin, hyper-echoic, clearly demarcated follicular walls of 
uniform thickness that is characteristic of a cohesive tissue layer (151). Hyperechoic free-
floating and protruding structures in the antral cavity are commonly observed (55). 
Luteinized unruptured follicles have thick follicular walls with an echotexture similar to 
luteinized tissue, an indistinct antral border and no point of follicle rupture (55).  
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Figure 2.6 a-f: Serial transvaginal ultrasonographic images of the right ovary of a research 
participant on days 1 (A), 4 (B), 7 (C), 11 (D), 16 (E), and 17 (F) of a spontaneous menstrual 
cycle demonstrating different stages of follicle and a luteal dynamics. The same ovarian 
follicle is identified throughout the growth phase (A-E) and the corresponding CL on the 
day following ovulation is shown (F) (from Baerwald, et. al, Fertility and Sterility, 2009)(261). 
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2.6.3. Ultrasonographic Image Characteristics of the Human Uterus 
The myometrium is displayed with homogenous echotexture and echoes of medium 
intensity (52, 55). The echotexture of the myometrium does not change during the menstrual 
cycle (55). The lumen of the uterus appears as a hyperechoic line from the fundus to the 
cervix in the sagittal plane. In the transverse plane, the uterine lumen appears as a horizontal 
hyperechoic line with the opposing layers of the endometrium appearing as an echoic oval 
surrounding the lumen (52).  
The echotexture of the endometrium varies throughout the menstrual cycle in 
concert with circulating concentrations of E2 and P4 (Figure 2.7)(55). An A pattern describes 
the echotexture immediately post menses and is observed as a hyper-echogenic thin, single 
line with no detectable differentiation of the stratum functionalis and basalis (262). During 
the early follicular phase, a faint triple line echotexture pattern is observed reflecting the 
separation of the stratum functionalis and basalis layers and is termed a B pattern (262). A C 
pattern is observed during the peri-ovulatory period of the follicular phase. It is 
characterized by a thick, pronounced triple line of hypo-echoic, hyper-echoic, and hypo-
echoic layers (262) which represents  pronounced differentiation of the stratum functionalis 
and basalis (262). A thick, homogeneous, moderate echotexture is the endometrial pattern 
typically observed during the luteal phase and is termed a D pattern (262). An M pattern is 
indicated when active menstrual flow is observed during menses and stratum functionalis 
and basalis appear as a hyperechoic, thin tissue layer (262).   
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Figure 2.7 a-e: Transvaginal ultrasonography of the endometrium in the sagittal plane with 
arrows identifying the anterior and posterior borders of the endometrium. The fundus of the 
uterus is to the left of the images and the cervix is to the top right of the images. The images 
illustrate the echotexture of an M pattern (A; day 3 of menses, active flow visualized), an A 
pattern (B; early follicular phase), a B pattern (C; mid-follicular phase), a C pattern (D; peri-
ovulatory period), a D pattern (E; mid-luteal phase)(from Baerwald, et. al, Ultrasound in 
Obstetrics and Gynecology, 2004)(262). 
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Chapter 3:  Rationale 
 Human ovarian folliculogenesis occurs in a wave-like pattern throughout the IOI. 
Two or three waves (or cohorts) of follicles develop through out an IOI. The final follicle 
wave in an IOI is ovulatory; an observation that is consistent across species. Recruitment of 
a cohort of follicles into a developing follicle wave is dependent upon a rise in FSH above a 
threshold level. In women, the pre-ovulatory follicle is selected for preferential growth over 
other follicles in the wave at approximately 10 mm in diameter. At this time, the aromatase 
enzyme complex in the dominant follicle becomes fully functional and the selected follicle 
produces increasing amounts of E2 (77). The selected follicle’s production of E2 induces the 
formation of LHr on the GC which then primes the dominant follicle for the mid-follicular 
phase surge in LH and subsequent OV.  
Emergency contraception was originally developed with the intent of suppressing 
follicular development, OV, or the ability of an embryo to implant in the uterus (28-30). 
However, the response of the ovaries to current hormonal EC is unpredictable. Exogenous 
E2 and P4 are effective at preventing pregnancy when administered at follicle diameters < 12 
mm (35, 236) although pregnancy is less likely to occur following unprotected intercourse at 
this time regardless of whether or not emergency contraceptives are administered. 
Emergency contraception does not inhibit OV when administered in the presence of a pre-
ovulatory dominant follicle ≥ 18 mm (33-36). Ancillary support for this reasoning is 
indicated by reports from Canada and the United States indicating approximately half of 
annual pregnancies (450,000 and 3.5 million, Canada and US respectively) are unintended 
and half of unintended pregnancies end in elective termination (263, 264). The inability of 
EC to prevent OV is problematic given the routine clinical use of the medication.  
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Aromatase inhibitors prevent the enzymatic conversion of androgens to estrogens 
and subsequently lower the concentration of serum estrogen (37-41). When AI are 
administered before selection as part of fertility treatments, pre-ovulatory sized follicles are 
typically observed 10 to 12 days later (42-49). The inhibition of aromatase prevents E2 
production and releases the hypothalamic/pituitary axis from the negative feedback of E2. 
The release results in an increase in FSH secretion and stimulation of further growth of the 
extant wave (44, 45, 49-51). Administration of AI in the presence of a selected follicle has 
not been documented. 
The rationale for the trial comprising the work in this thesis was developed from the 
idea that a non-steroidal AI would cause an acute drop in E2 at physiologically critical time 
points of the natural menstrual cycle based on observations from infertility treatments and 
EC. The dose selected was based on reports of multiple and single dose regimens in fertility 
therapy and is slightly less than half the maximal multiple dose regimen. We theorized that if 
AI were administered after follicle selection the acute E2 deprivation would initiate atresia of 
the dominant follicle in the extant wave, as is observed in defined time OC administration. 
Estradiol deprivation would be expected to release negative feedback on FSH and result in 
the emergence of a new follicular wave without an ovulatory event occurring.  
We anticipate that our study will increase our understanding of the role of E2 in 
follicle selection, OV induction, and early luteal formation. A greater understanding the 
control of human ovarian dominant follicle selection, OV induction, and early CL 
development has implications in the development of emergency contraceptives and fertility 
treatments. Information regarding the mechanisms of follicular wave emergence, dominant 
follicle selection, and CL formation could be used to develop novel ways to use current 
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hormonal contraceptives, develop new contraceptive technologies, and provide more 
contraceptive choices for women. 
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Chapter 4:  General Objectives and Hypotheses 
The general objectives of the study contained in this thesis were to: 
1. characterize ovarian follicular and luteal development following AI administration 
post selection in the follicular phase; 
2. characterize the endometrial response to AI administration post selection in the 
follicular phase; and,  
3. assess the response of FSH, LH, E2, and P4 to AI administration post selection in the 
follicular phase. 
 
We hypothesized that a single 20 mg dose of AI administered at peri-selection diameter, 
pre-ovulatory diameter, or 24-48 hours post-OV in the natural menstrual cycle would cause 
ovulatory failure and/or failure of CL formation which would be associated with arrested 
endometrial development, a shortened interval to menses, and new follicular wave 
emergence. We hypothesized that a single 20 mg dose of AI at these times would cause an 
acute drop in E2 which would be associated with a rise in FSH and no change in LH. 
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Chapter 5:  A single 20mg dose of aromatase inhibitor does not inhibit 
folliculogenesis or luteogenesis  
Allaway, H.C.M.1; Chizen, D.R.1; Adams, G.P.2; Pierson, R.A.1 
 1 Department of Obstetrics, Gynecology & Reproductive Sciences, College of Medicine, University of 
Saskatchewan, Saskatoon, Saskatchewan 
2 Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, University of 
Saskatchewan, Saskatoon, Saskatchewan   
Abstract 
Introduction:  Ovarian folliculogenesis occurs in a wave-like pattern of growth during the 
menstrual cycle. A better understanding of the role of estrogen in folliculogenesis may lead 
to the development of better contraceptive and fertility protocols. Aromatase inhibitors 
cause a transient decline in natural estrogen production. Multiple small doses of an 
aromatase inhibitor have been used during fertility therapy to induce dominant follicle 
growth and ovulation. 
Objectives:  Our objectives were to elucidate the effects of a single 20 mg dose of an 
aromatase inhibitor (Letrozole/FemaraTM) on folliculogenesis and test the hypothesis that an 
AI administered during defined times of the follicular phase or immediately after ovulation 
would result in atresia of the extant dominant follicle and initiate new wave emergence. 
Methods:  Healthy, reproductive age, female volunteers not taking hormonal contraceptives 
were recruited (n=41). Ultrasound examinations began on day 4 of the menstrual cycle (day 
1=first day of menses). Volunteers were randomized into 1 of 4 groups: treatment at a 
follicle diameter of 1) 12 mm, 2) 18 mm, 3) the first day following ovulation, or 4) control. 
Serial ultrasonography and phlebotomy were performed until ovulation in the subsequent 
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cycle. Differences were analyzed using t-test, ANOVA, repeated measures ANOVA, or 
Kruskal-Wallis ANOVA where appropriate.  
Results:  The dominant follicle in all treatment groups ovulated. There were no differences 
among experimental groups for peak follicle diameter, follicular growth rate, endometrial 
thickness at ovulation, or inter-ovulatory interval. Maximum FSH concentrations in the 12 
mm, 18 mm and post-OV groups were 12.58 ± 1.41 mIU/mL, 18.62 ± 2.27 mIU/mL, 12.38 
± 1.10 mIU/mL, respectively. Maximum LH concentrations in the 12 mm, 18 mm and post-
OV groups were 16.20 ±2.06 mIU/mL, 40.43 ± 4.32 mIU/mL, 16.34 ± 2.59 mIU/mL, 
respectively. The 18 mm group had higher FSH and LH concentrations (P < 0.02) compared 
to the 12 mm and post-OV groups.  
Conclusions:  Administration of a single 20 mg dose of an aromatase inhibitor at defined times 
of the menstrual cycle did not induce dominant follicle regression or new wave emergence. 
Treatment resulted in continued follicle development, a transient decrease in E2 levels and 
elevated circulating FSH and LH concentrations. The failure of an aromatase inhibitor to 
interrupt dominant follicle development suggests a compensatory mechanism for the acute 
drop in E2 that may involve increased LH and FSH levels.  
Introduction 
The suppression of follicular development, ovulation (OV), or the ability of an 
embryo to implant is the intent of emergency contraception (EC) in clinical practice (29, 30). 
Emergency contraceptive regimens use various formulations of exogenous estrogens and 
progestins to prevent pregnancy and are now available ‘over-the-counter’ in many countries 
around the world, including Canada (265, 266). The use of EC by women is increasing as 
women become aware of the availability of post-coital means of preventing pregnancy (267, 
268).  
  45 
The ovarian response to EC regimens is unpredictable and OV is not inhibited when 
EC are administered near the time of natural OV (28, 34-36). Ancillary support for the need 
of more effective EC is indicated in data from Statistics Canada (269, 270). In Canada 
approximately 450,000 pregnancies are documented annually - approximately 120,000 end in 
elective termination (269, 270). In the United States there is a similar trend, 3.5 million 
pregnancies occur annually, 1.72 million are unintended and nearly 1 million unintended 
pregnancies end in elective termination (263, 264). 
Women are educated about their menstrual cycles based on the traditional theory of 
follicle development. The traditional theory states that the human menstrual cycle is 
visualized from the first day of menses to the day before the next first day of menses (20, 
66). Menstruation is the external sign of reproductive cyclicity in women. The traditional 
theory also states that a single cohort of antral follicles is recruited for growth in the late 
luteal phase (20, 66). Transvaginal ultrasonography has facilitated the use of OV as the 
definitive endpoint of the reproductive cycle. Follicle growth is thus observed from OV to 
OV, which is termed the “inter-ovulatory interval” (IOI). Ultrasonography has also 
facilitated the identification and characterization of wave-like patterns of antral follicle 
growth during the human menstrual cycle (3, 18). Documentation of follicular waves in 
women is consistent with follicular wave dynamics of the estrus cycle in several domestic 
animal species (78, 84, 90, 92, 271). When the menstrual cycle in women is observed over an 
IOI menses occurs in the middle of the IOI and the final wave that occurs is ovulatory. 
Current formulations and administration regimens of hormonal EC are based on the 
traditional theory of follicle development. These methods are intended for use up to 120 
hours after contraception failure or unprotected intercourse (222, 223, 227, 272, 273). The 
two standard methods available in Canada are Plan BTM, 0.75 mg of levonorgestrel, and the 
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Yuzpe method, 0.1 mg ethinyl estradiol and 0.5 mg levonorgestrel (28, 35, 227, 272). Both 
methods require two doses to be taken 12 hours apart. Ovarian follicular development and 
OV in women have been studied after use of both regimens; however, the mechanisms 
underlying follicular growth, regression and OV following EC use remain poorly elucidated 
(28, 35, 36, 274). The mechanism of action was different with each regimen and depended 
upon the relative timing between intercourse, administration, and expected OV (28, 35). The 
two main hypotheses to explain the contraceptive action of EC are the prevention of 
fertilization and implantation (30, 233-236). Hormonal EC is most effective if administered 
when the dominant follicle diameter is small (i.e., 4 to 5 days prior to expected OV); 
however, during this time interval intercourse is less likely to result in pregnancy whether or 
not EC is administered (28, 34-36). 
Aromatase inhibitors (AI) prevent the enzymatic conversion of androgens to 
estrogens (41, 50, 51). Letrozole (FemaraTM) is a non-steroidal aromatase inhibitor that 
reversibly binds to and inactivates the aromatase enzyme (48, 182, 183). Letrozole was 
designed as an adjuvant therapy in estrogen positive post-menopausal breast cancer (275, 
276). Letrozole also has been used for the treatment of infertility (50, 203). Administration 
of AI before follicle selection was proposed to temporarily release the hypothalamic-pituitary 
axis from estrogenic negative feedback (44, 46, 49-51). The feedback release would result in 
increased FSH secretion and stimulate further growth of the extant wave. Growth of a 
dominant follicle would increase E2 secretion and induce normal negative feedback at the 
hypothalamic-pituitary axis (44, 46, 49-51). Following this proposed mechanism of action, 
small 5-day dose and large single dose regimens of letrozole have been used successfully to 
induce follicle growth (45, 182, 206). The small sample sizes in studies utilizing letrozole 
prevent conclusions about the efficacy of AI in OV induction from being complete.  
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Recently, the effects of a single or 3 day intravenous dose of letrozole on 
folliculogenesis in beef heifers has been evaluated. Letrozole therapy did not induce follicular 
atresia, hasten new follicular wave emergence, or induce increased FSH concentrations when 
administered in anovulatory or ovulatory waves (277, 278). Letrozole administration in 
heifers increased plasma LH concentrations and extended the period of follicle dominance 
that led to delayed emergence of the next follicular wave (277).  
Based on evidence from EC reports we proposed that after follicle selection antral 
follicles would respond differently to AI treatment compared with known pre-selection 
responses to AI in fertility therapy. The overall objectives of the present study were to: 1) 
characterize ovarian follicular, luteal and endometrial development following a single 20 mg 
dose of an AI (Letrozole/FemaraTM) using high-resolution transvaginal ultrasonography; 
and, 2) to assess the response of FSH, LH, and E2 to a single 20 mg dose of letrozole. We 
hypothesized that a single 20 mg dose of letrozole administered at defined points of follicle 
development in the natural menstrual cycle would cause ovulatory failure and/or failure of 
CL formation and be associated with arrested endometrial development, a shortened interval 
to menses, and new follicular wave emergence. We also hypothesized that a single 20 mg 
dose of letrozole at defined times of follicle development would cause a transient drop in E2 
which would be associated with a rise in FSH and no change in LH. The defined points of 
follicle development were chosen to represent peri-selection (12 mm), pre-ovulatory (18 
mm), and post-ovulatory (24 hours post-OV). 
Materials and Methods 
A prospective, randomized, controlled, single centre, open label trial was conducted. 
The study protocol was approved by the Biomedical Research Ethics Review Board at the 
University of Saskatchewan and Health Canada. All study procedures were conducted in full 
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compliance with the Tri-Council Policy Statement on the Ethical Conduct for Research 
Involving Humans, ICH Good Clinical Practice Guidelines and Declaration of Helsinki at 
the Women’s Health Imaging Research Laboratory at the University of Saskatchewan.   
Participants 
Forty-one women between the ages of 18 and 35 years (25.48 years ± 0.86) with a 
body mass index (BMI) of 18 to 32 (25.04 ± 0.55) were enrolled. Informed consent was 
obtained from all women prior to the initiation of study procedures. All participants were 
non-smoking, healthy women with regular menstrual cycles and no contraindication to 
contraceptive or AI use (as determined following medical history and physical examination). 
The women were required to have discontinued use of hormonal contraceptives 2 or more 
months prior to beginning the study. Participants were asked to abstain from intercourse 
during the study; however, participants were also provided with barrier contraceptives 
(condoms) throughout the study to prevent pregnancy. 
Treatments 
Women were randomly assigned to 1 of 4 experimental groups at the first 
ultrasound: AI administration 1) at a first detection of a 12 mm ± 1 mm follicle diameter in 
the follicular phase (n = 10), 2) at an 18 mm ± 1 mm follicle diameter in the follicular phase 
(n = 10), 3) within 24 hours of OV (n = 10), and 4) a contemporaneous no treatment 
control group (n = 11). The randomization procedure was a randomized complete block 
design. All women in the treatment groups received a single 20 mg dose of letrozole 
(FemaraTM, Novartis Pharmaceuticals Canada Inc, Dorval, Quebec) when they reached the 
follicle size at which they were randomized to receive treatment. Participants were followed 
for 1.5 menstrual cycles (one inter-menstrual interval, followed by the interval from menses 
to OV of the next cycle). The experimental period was defined as 5 sequential days 
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beginning on the day of treatment. A schematic representation of the study protocol, 
treatment initiation, ultrasound, and phlebotomy is shown (Figure 5.1). 
 
Figure 5.1: Schematic diagram of the study protocol.  
 
Ultrasonography 
Ovarian follicular and endometrial development were evaluated using transvaginal 
ultrasonography (Ultrasonix RP, Ultrasonix, Inc., Vancouver, BC). One individual 
performed approximately 96% of the examinations (HCMA). Three other investigators 
(TGBS, RAP, HVB) performed examinations when the primary ultrasonographer was 
unavailable. All examinations were conducted in accordance with standard operating 
procedures for ultrasonographic imaging at the Women's Health Imaging Research 
Laboratory.  
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Ultrasonographic scanning began on day 4 of the menstrual cycle (day 1 = first day 
of menses). Scans were performed every other day thereafter until randomization status was 
met. Following administration of letrozole, ultrasound examinations were performed daily 
for a minimum of 11 days and were continued daily until the fate of the dominant follicle 
was determined (i.e., regression, formation of an anovulatory follicular cyst, hemorrhagic 
anovulatory follicle (HAF), luteinized unruptured follicle (LUF), or OV). After 
determination of follicular fate, ultrasound examinations then returned to an every other day 
schedule until the dominant follicle of the next ovulatory wave reached 15 mm ± 1 mm. 
Daily examinations then resumed until the subsequent OV.  
Diameters of all follicles ≥ 2 mm were tabulated at each ultrasound examination. 
The average of the mean follicle length and width in the transverse and sagittal planes was 
used as the mean follicle diameter for all follicles > 10 mm. The dominant follicle was 
defined as the follicle ≥ 10 mm that surpassed other follicles in the cohort by ≥ 2 mm in 
diameter. A co-dominant follicular wave was defined as a wave with 2 or more dominant 
follicles. Ovulation was defined as the disappearance of a follicle ≥ 12 mm in diameter 
detected ultrasonographically the previous day followed by the subsequent visualization of a 
luteal structure (152, 159). 
Endometrial thickness and pattern were also recorded during each ultrasound 
examination as previously described (262, 279). Endometrial thickness was defined as the 
distance from the anterior stratum basalis-myometrial junction to the posterior stratum 
basalis-myometrial junction measured in the mid-sagittal plane at the largest dimensions of 
the fundal aspect of the uterus. Endometrial echotexture was assessed each scan as either an 
M, A, B, C, or D pattern.  
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Blood Sampling 
All participants had blood drawn to measure serum concentrations of E2, P4, FSH 
and LH at specific time points throughout the study. Beginning on the day of treatment, 
blood was drawn daily for 5 days to measure changes in endocrine concentration following 
treatment. If the fate of the extant follicle was not determined after 5 days, blood was drawn 
every other day until follicle fate was determined. A subsequent blood draw was performed 5 
to 9 days after the determination of dominant follicle fate to confirm follicle fate with P4 
levels. A final blood sample was taken when the subsequent pre-ovulatory follicle reached 18 
± 1 mm. Participants in the control group had a single blood sample drawn at the 
physiologic times (12 mm follicle, 18 mm follicle, 24 hours post OV) when treatment group 
participants would have administered treatment. Control group participants also had a final 
blood sample taken when the subsequent pre-ovulatory follicle reached 18 ± 1 mm. 
Blood samples were collected into a 7 mL tube and allowed to coagulate for 30 to 45 
minutes (min) at room temperature before centrifugation for 30 min at 700 x g. Serum was 
isolated and stored at -20°C until all participants had completed the study. 
Daily Events Charts 
All volunteers were provided a diary to record menstrual patterns, concomitant 
medication and any adverse events that occurred during the study.  
Imaging Data Analysis 
The identity and non-identity methods were used to characterize changes in follicle 
diameter during the study (90, 280). The non-identity method requires sorting all follicles ≥ 2 
mm in descending order of diameter for left and right ovaries for each woman at each study 
visit separately. The size sorted follicles in left and right ovaries were then graphed over time. 
The identity method involved sketching the sizes and locations of all follicles ≥ 2 mm in 
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each ovary immediately after each scan (18, 271, 277, 281). The day-to-day identities of 
individual follicles were determined retrospectively using the size and anatomic location of 
the ovary with respect to the uterus as reference points. The diameter profiles of individual 
follicles that grew ≥ 8 mm over time for each woman were graphed (18). Mean growth 
profiles of the dominant and first subordinate follicles were graphed for each study group. 
Mean endometrial thickness profiles over the course of the study were also plotted for each 
group. 
Hormone Assays 
Sequential competitive fluorescence immunoassays (ImmuliteTM, Siemens Healthcare 
Diagnostics Inc., Tarrytown, NY) were performed to measure serum FSH and LH levels. 
Sequential radioimmunoassays were performed to measure serum E2 and P4 concentrations. 
All assays were conducted at Prairie Diagnostic Services at the University of Saskatchewan. 
Minimal detectible limits were: FSH (0.1 mIU/mL), LH (0.1 mIU/mL), E2 (1.4 pg/mL), and 
P4 (0.02 ng/mL). Intra-assay coefficients of variation for control measurements of secondary 
antibodies were as follows: FSH (low = 3.0%, medium = 2.9%, high = 1.6%), LH (low = 
2.6%, medium = 2.4%, high = 1.6%), E2 (low = 2.4%, medium = 10.9%) and P4 (low = 
3.9%, medium = 6.3%, high = 7.6%).  
Statistical Analyses 
Statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). 
Descriptive statistics for single point measurements were analyzed among groups using one-
way ANOVA. Hormone concentrations on day of treatment were compared between 
groups using t-tests. Changes in hormone concentration (E2, FSH, and LH) over time were 
analyzed using repeated measures ANOVA (PROC MIXED). Endometrial thickness, 
endometrial pattern and intervals from treatment to OV were compared using Kruskal-
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Wallis ANOVA. Significance was set at P < 0.05. Results are expressed as the mean ± SEM. 
The magnitude of the drop in estradiol was defined by the equation ([E2 day of treatment]– 
[E2 day of nadir])/(day of nadir – day 1). 
Results 
The age, BMI, and waist-hip ratio (WHR) of participants were similar among groups 
(P > 0.3; Table 5.1). No adverse events were observed in any of the groups.  
Table 5.1:  Descriptive statistics for age (years), BMI (kg/m2), and WHR (mean ± SEM) of  
participants. 
 
Experimental Group  N Age (years) BMI (kg/m2) WHR 
12 mm 10 24.80 ± 1.92 25.36 ± 0.80 0.75 ± 0.01 
18 mm 10 28.00 ± 1.58 24.54 ± 1.12 0.76 ± 0.02 
Post OV 10 24.00 ± 1.58 24.80 ± 1.40 0.75 ± 0.01 
Control 11 25.18 ± 1.76 25.41 ± 1.12 0.79 ± 0.02 
 
Follicular Dynamics 
The mean diameter profiles of the dominant and first subordinate follicles of the 
ovulatory wave and the largest and second largest follicles of the first anovulatory wave for 
each experimental group are shown (Figures 5.2 to 5.5). The dominant follicles in all study 
groups ovulated. Ovulation was confirmed by ultrasonographic observation of a CL and a 
subsequent rise in P4 on days 5-9. In the 12 mm group, 3 of 10 (30%) women developed co-
dominant follicles, one follicle ovulated and the other regressed (n = 1) or double OV (n = 
2) occurred. One of 10 (10%) women in the 18 mm group developed co-dominant follicles, 
one follicle ovulated and the other regressed. In the control group, one woman (18%) 
developed co-dominant follicles, one follicle ovulated and the other developed into a HAF. 
This participant was excluded from hormonal analysis. 
The day of treatment and the interval from treatment to OV differed among 
treatment groups (P < 0.0001; Table 5.2). The day of treatment was earlier in the 12 mm 
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group and later in the 18 mm and post OV groups based on physiology and experimental 
design. The 12 mm group peak follicular diameter was larger compared the 18 mm and 
control groups (P < 0.04). The peak follicular diameters of the 12 mm and post-OV groups 
did not differ (P = 0.1251). Peak follicular diameter did not differ between the 18 mm, post-
OV and control groups (P > 0.5). The interval from treatment to OV was longest in the 12 
mm group and shortest in the 18 mm group. The interval from treatment to OV in the post 
OV group was negative because participants were administered treatment 24 hours following 
OV. There were no differences among study groups for follicular growth rate (P > 0.1; 
Table 5.2). Daily changes in dominant follicle growth are shown (Figure 5.6). 
The interval from detection of an 18 mm follicle to OV was shorter in the 18 mm 
treatment group than in the control group (41.78 ± 13.12 h vs. 72.54 ± 34.92 h, respectively; 
P = 0.006). The interval from treatment to new follicular wave emergence was longer in the 
12 mm group (7.7 ± 6.0 d) compared to the 18 mm and post OV groups (1.3 ± 2.8 d, -0.5 ± 
3.0 d, respectively; P = 0.0001). The 12 mm, 18 mm, post OV and control groups had 
similar intervals from OV to new follicular wave emergence (0.4 ± 4.5 d, -0.2 ± 2.5 d, 0.5 ± 
3.0 d, 0.8 ± 3.2 d, respectively; P = 0.925). 
Table 5.2: Mean follicular end points (mean ± SEM) among experimental groups. 
 
Experimental 
Group 
N Day of 
treatment (d) 
Peak diameter 
(mm) 
Follicular growth 
rate (mm/d) 
Interval from 
treatment to OV (d) 
12 mm 10 9.2 ± 0.4a 23.2 ± 1.0a 1.5 ± 0.1a 7.4 ± 0.6a 
18 mm 10 14.5 ± 1.1b 19.8 ± 0.6b 1.3 ± 0.1a 1.9 ± 0.2b 
Post OV 10 17.9 ± 0.8c 20.7 ± 1.3a,b 1.5 ± 0.1a -1.0 ± 0.0c 
Control 11 NA 19.8 ± 1.4b 1.2 ± 0.1a NA 
P-value  0.0001 0.1266 0.1809 0.0001 
All comparisons are within columns. Values with different superscripts indicate differences 
among experimental groups (P < 0.05). a-c Comparisons among experimental groups. 
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Figure 5.2 a-c: Mean follicle diameter profiles of the 12 mm group. Participants with 
follicles that ovulated (A), ovulated and regressed (B), and double ovulated (C) are shown 
separately. Data are shown for one inter-menstrual interval centralized to the day of 
treatment at 12 mm. The ovulatory wave dominant (■) and 1st subordinate (□) follicles and 
the anovulatory wave largest (●) and second largest (○) follicles are shown.  
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Figure 5.3 a & b: Mean follicle diameter profiles of the 18 mm group. Participants with 
follicles that ovulated (A) and ovulated and regressed (B) are shown separately. Data are 
shown for one inter-menstrual interval centralized to the day of treatment at 18 mm. The 
ovulatory wave dominant (■) and 1st subordinate (□) follicles and the anovulatory wave 
largest (●) and second largest (○) follicles are shown.  
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Figure 5.4: Mean follicle diameter profiles of the post-OV group. Data are shown for one 
inter-menstrual interval centralized to the day of treatment 24 hours after observation of 
OV. The ovulatory wave dominant (■) and 1st subordinate (□) follicles and the anovulatory 
wave largest (●) and second largest (○) follicles are shown. 
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Figure 5.5 a & b: Mean follicle diameter profiles of the control group. Participants with 
follicles that ovulated (A) and ovulated and formed a HAF (B) are shown separately. Data 
are shown for one inter-menstrual interval centralized to the day of OV. The ovulatory wave 
dominant (■) and 1st subordinate (□) follicles and the anovulatory wave largest (●) and second 
largest (○) follicles are shown. 
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Figure 5.6 a-d: Dominant follicle growth over the follicular phase centralized to OV (A). 
Daily differences in dominant follicle growth centralized to day of treatment (day 1) for the 
12 mm (B), 18 mm (C), and post-OV (D) groups. Daily differences in dominant follicle 
growth are compared to daily differences in dominant follicle growth in the control group 
centralized to the respective treatment initiation size. 
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Circulating Hormone Concentrations 
The E2 concentrations between each treatment group and the control group assessed 
at the same follicle diameter did not differ (P > 0.25; Table 5.3). The pattern of change in 
plasma E2 concentration over 5 days beginning on the day of treatment differed among the 3 
treatment groups (P < 0.0001; Figure 5.7). The 18 mm group exhibited higher (P < 0.0001) 
E2 concentrations on the day of treatment attributed to the presence of a pre-ovulatory 
dominant follicle. Following treatment E2 concentrations decreased in all treatment groups 
(P = 0.0004). The 18 mm group E2 levels reached baseline on day 3 and remained at baseline 
until day 5 (P = 0.8563). The 12 mm group E2 levels increased (P = 0.01) from day 2 to day 
5. The magnitude of the initial drop in E2 concentration in the 18 mm group was larger than 
in both the 12 mm and post OV groups (P = 0.04; Figure 5.8).  
Table 5.3: Mean E2, FSH, and LH concentrations on the day of treatment in each treatment  
     group compared to the control group at the same respective time in the menstrual  
     cycle. 
 
 E2 
(pg/mL) 
FSH 
(mIU/mL) 
LH 
(mIU/mL) 
12 mm group 40.33 ±   3.94a 5.61 ± 0.37 6.1 ± 0.50 
Control group at 12 mm 53.05 ± 13.23a NA NA 
18 mm group 131.9 ± 12.06p 6.72 ± 1.13 21.46 ± 6.02p 
Control group at 18 mm 160.2 ± 10.19p NA 17.79 ± 4.65p 
Post OV group 66.53 ± 10.19t 5.05 ± 0.84t 7.43 ± 1.53t 
Control group post OV 49.77 ± 13.87t 4.17 ± 0.42t 7.04 ± 1.18t 
All comparisons are within columns and physiologic time. Values with different superscripts 
indicate differences (P < 0.05). a Comparisons between 12 mm and control groups.  
p Comparisons between 18 mm and control groups. t Comparisons between post OV and 
control groups. 
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Figure 5.7: Mean changes in E2 concentration over the experimental period in the treatment 
groups (day 1 = day of treatment). Differences among treatment groups are identified within 
days (P < 0.05). * Within day comparisons among experimental groups. 
 
 
Figure 5.8: Drop in E2 concentration from initial to nadir in the experimental period in the 
treatment groups. Differences among treatment groups are denoted by different 
superscripts. a,b Differences among experimental groups drop in E2 concentrations to nadir. 
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interaction was attributed to the immediate FSH increase from day 1 to 2 in the 12 and 18 
mm groups (P < 0.0001), while FSH levels in the post OV group first increased from day 2 
to 3 (P < 0.0002). FSH concentrations in the 18 mm group were higher than those of the 12 
mm and post OV groups (P < 0.007). FSH concentrations were highest in the 18 mm group 
on days 2, 4 and 5 following treatment (P < 0.03).  
 
Figure 5.9: Mean changes in FSH concentration over the experimental period (day 1 = day 
of treatment) in the treatment groups. Differences among treatment groups are identified 
within days (P < 0.05). * Within day comparisons among experimental groups. 
 
Following treatment, plasma LH concentrations in all treatment groups initially 
increased (P = 0.0013; Figure 5.10). LH concentrations then decreased to pretreatment levels 
by the end of the experimental phase (P = 0.6329). The mean plasma LH concentrations 
over the experimental period were higher in the 18 mm group versus the 12 mm and post 
OV groups (P < 0.02). 
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Figure 5.10: Mean changes in LH concentration over the experimental period (day 1 = day 
of treatment) in the treatment groups. Differences among treatment groups are identified 
within days (P < 0.05). * Within day comparisons among experimental groups. 
 
The maximum concentrations of FSH and LH following treatment differed among 
treatment groups (P < 0.03; Figure 5.11). The 18 mm group had higher FSH and LH 
concentrations than the 12 mm and post OV groups (P < 0.05); maximum FSH and LH 
concentrations did not differ between the 12 mm and post OV groups (P > 0.26). The 
interval from the day of treatment to the day of maximum FSH was 2 days for the 12 mm 
group, 4 days for the 18 mm group and 3 days for the post OV group (P = 0.0254). The 
interval from the day of treatment to the day of maximum LH concentrations tended to be 
shorter for the 12 and 18 mm groups versus the post OV group (P = 0.0833). 
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Figure 5.11: Mean maximum FSH and LH concentrations during the experimental period. 
Overall comparisons among treatment groups are denoted by different letters. a,b differences 
among treatment groups peak FSH concentrations. c,d differences among treatment groups 
peak LH concentrations. 
 
Endometrial and Luteal Dynamics 
Mean maximum endometrial thickness and pattern, and endometrial thickness and 
pattern at ovulation were not different among experimental groups (P > 0.1124; Figure 
5.12). There were no differences in the interval from menses to OV, IOI, or IMI among 
experimental groups (P > 0.2; Table 5.4). Day 5-9 serum P4 concentrations were 22.85 ± 
5.46, 16.33 ± 1.84, 13.01 ± 1.41 and 24.12 ± 5.67 in the 12 mm, 18 mm, post-OV and 
control groups, respectively (mean ± SEM; P = 0.1899). Based on no differences among 
groups with regard to P4 levels, IMI and IOI there was no effect of treatment on CL 
formation. The 12 mm and 18 mm groups had longer intervals from treatment to menses 
than the post-OV group based on physiology (P < 0.0001; Table 5.4). 
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Table 5.4: Descriptive statistics for physiologically relevant intervals (mean ± SEM) among  
      experimental group comparisons. 
 
Experimental 
Group 
N Interval from 
menses to OV (d) 
Inter-menstrual 
interval (d) 
Inter-ovulatory 
interval (d) 
Interval from treatment 
to menses (d) 
12 mm 10 16.6 ± 0.5a 27.6 ± 1.1a 29.5 ± 1.6a 19.7 ± 1.3a 
18 mm 10 16.4 ± 1.1a 29.6 ± 1.4a 26.9 ± 2.0a 16.1 ± 0.6b 
Post OV 10 16.9 ± 0.8a 28.0 ± 1.0a 23.9 ± 3.0a 11.1 ± 0.9c 
Control 11 17.2 ± 1.0a 28.5 ± 1.1a 29.0 ± 1.1a NA 
P-value  0.9284 0.6551 0.2014 0.0001 
All comparisons are within columns. Values with different superscripts indicate differences 
(P<0.05). a-c Comparisons between experimental groups. 
 
 
Figure 5.12 a & b: Mean profiles of endometrial thickness (A) and pattern (B). Women in 
all experimental groups, 12 mm (■), 18 mm (□), 24 hours post ovulation (●), and control (○), 
are identified. Data are shown for one inter-menstrual interval and are centralized to the day 
of ovulation. No significant effect of day observed for endometrial thickness or pattern. 
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Discussion 
Our hypothesis that a single 20 mg dose of letrozole given at defined times of the 
natural menstrual cycle would cause ovulatory failure and failure of CL formation or 
impaired luteogenesis was not supported. Similarly, arrested endometrial development, 
emergence of a new follicular wave, and a shortened interval to menses were not observed. 
Our hypothesis that letrozole administered at defined times of the menstrual cycle resulted 
in a drop in E2 and a rise in FSH was supported; however, our hypothesis that there would 
be no change in LH was not supported. 
Treatment administered peri-selection of a dominant follicle (i.e., the 12 mm group) 
was provided to determine the effects of E2 deprivation on pre-ovulatory follicle growth. In 
this group the selected follicle continued to grow an attained a larger pre-ovulatory size 
compared with the other pre-ovulatory treatment group (i.e., 18 mm group) and control 
group. When treatment was provided at an ostensibly pre-ovulatory size (i.e., the 18 mm 
group) there was no change in follicle diameter at OV compared to the control group. There 
was a tendency for the pre-ovulatory follicle diameter in the 12 mm group to be larger 
compared to the post-OV group. The trend of a larger follicle in the 12 mm group suggests 
that there is a compensatory mechanism for the acute drop in E2 in the mid-follicular phase. 
We postulated that this compensatory mechanism was a result of a rise in FSH and LH that 
was observed following AI treatment. However, with our small sample size we were unable 
to conclude that AI treatment effects pre-ovulatory follicle diameter. 
Treatment in the follicular phase did not alter the growth profile of the dominant 
follicle in the present study. This is contrary to results reported in domestic farm animals. In 
the bovine species, a single dose of letrozole after follicle selection prolonged the interval 
from treatment to OV (277, 278, 282). To date there has been no evaluation of the effects of 
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AI on follicle growth profiles when administered prior to dominant follicle selection. 
Dominant follicle selection during natural human menstrual cycles is thought to occur at a 
mean diameter of approximately 10 mm (34). Initiation of AI treatment prior to selection as 
used in ovarian stimulation had a different effect on extant follicle development. Use of AI 
prior to selection may have more effectively released FSH secretion stimulating further 
growth of the extant follicular wave; however, studies did not measure changes in FSH 
during treatment (44, 45, 48, 50, 51, 150, 182, 183, 201, 206-209, 215, 283-287). In 
retrospect, it would have been useful to include a treatment group in which women received 
letrozole after day 3 and before the largest follicle attained a diameter of 10 mm. The use of 
this strategy may provide insight into the roles of FSH concentration and E2 during 
selection. 
Follicle development in all treatment groups continued despite a drop in E2 
production following letrozole treatment in women. Decrease in E2 was observed within 24 
hours of letrozole treatment in all women in our treatment groups, supporting our 
hypotheses. These findings contrast those previously documented in the bovine species, 
where increasing mean plasma E2 levels were observed for 4 days following the day of 
letrozole treatment. The E2 increase was associated with a simultaneous increase in follicle 
diameter (282). In the present study, only women the 12 mm group had an increase in E2 
level following letrozole use in the follicular phase. Estradiol levels were not available for 
comparison during the same time frame in the control group. An increase in E2 
concentration began 2 days after treatment and was attributed to the continued growth of 
the pre-ovulatory dominant follicle. The absence of a rise in E2 following 18 mm and post-
OV group treatments can be attributed to a physiologic drop in E2 secretion following OV, 
as documented in previous studies of natural cycle OV (3).  
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A rise in FSH following treatment observed in all treatment groups in the present 
study supported our hypothesis. Treatment with letrozole in the luteal phase in women 
resulted in a FSH rise 7 days after treatment (288). However, increases in FSH concentration 
in women contrast with the lack of FSH change in response to letrozole treatment 
previously reported in the bovine species (277, 278, 282). The pattern of FSH rise in all three 
treatment groups differed; however, all three groups exhibited a rise in FSH for the 4 days 
following treatment to typical mid-follicular phase levels. In natural menstrual cycles, the 
duration of the FSH rise at wave emergence is short due to the negative feedback system of 
E2 and inhibin B. This mechanism is postulated to ensure monovulation (106). The 4-day 
rise in FSH following letrozole treatment appears to elongate the FSH rise thus potentially 
allowing multiple dominant follicles to develop.  
In the present study, women in the 12 mm, 18 mm and control groups developed 
co-dominant follicles. In the 12 mm group, 20% of the women ovulated 2 follicles during 
the treatment period, in contrast with the reported 4% natural occurrence of double OV (88, 
159, 289, 290). Another participant in the 12 mm group developed a second dominant 
follicle which regressed. This observation is conceptually similar to a recent study in cattle 
wherein the 1st subordinate follicle of animals given AI in the follicular growth phase (d1-3) 
exhibited larger mean diameters (277). It was postulated that the extended FSH window in 
women allowed a subordinate follicle to be rescued from atresia. In both the 18 mm and 
control groups, a second dominant follicle grew but either regressed (10%) or resulted in 
ovulatory failure (9%). Ovulatory failure occurs in approximately 5% of cycles of regularly 
cycling women (291) and 10% of cycles in infertile women (260, 292). We did not see an 
increased incidence of ovulatory failure in this study. 
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Circulating LH concentrations reached maximum levels within 24 hours of treatment 
and returned to starting levels by the end of the experimental period in all groups. The rise in 
LH concentrations within 24 hours is consistent with reports of letrozole treatment in cattle 
(277, 278, 282). An increase in mean LH concentration in women has only previously been 
shown on day 6 of a 7 day low dose follicular phase letrozole treatment (293). A sustained 
elevation in LH following cessation of follicular phase AI treatment has not previously been 
reported in women (42-45, 47, 48, 196, 198, 203, 206, 208, 285, 293, 294). Most reports 
involving the use of AI in women are based on research in fertility patients where chemical 
and clinical pregnancy were the final outcome measures (42-45, 47, 48, 196, 198, 203, 206, 
208, 285, 294). In these reports, LH concentration is measured only after hCG is given to 
induce OV (42-45, 47, 48, 196, 198, 203, 206, 208, 285, 293, 294). In bovine studies, it has 
been suggested that the prolonged elevation in LH following AI treatment in the follicular 
and luteal phases indirectly enhances dominant follicle development (277, 278, 282).  
The failure of letrozole to interrupt follicle development in the 12 mm and 18 mm 
groups in the present study indicates a potential post-selection compensatory mechanism for 
an acute drop in estrogen production. The mechanism may involve an indirect enhancement 
of follicle growth by an increase in LH levels, as inferred from observations in the bovine 
model (277, 278, 282). In humans a post letrozole treatment increase in LH levels in concert 
with a similar increase in FSH levels may facilitate continued follicular development.  
Limitations in our study design are related to the unexpected study outcomes that we 
observed. We hypothesized that letrozole treatment would result in ovulatory failure and 
hence did not anticipate that a need would arise for the evaluation of serial luteal phase P4. 
The issues arising from the experimental design with respect to the control group blood 
collection were the biggest limitations of the study. Blood draws in the control group were 
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collected to coincide with the times of letrozole treatment at defined times: peri-selection, 
pre-ovulatory, and post-OV. This experimental design did not allow for adequate endocrine 
comparisons between the treatment and control groups during the experimental period. 
However, the optimal design facilitating comparison of the control group to the treatment 
groups during the experimental period would have required volunteers to have had blood 
collected daily for approximately 15 consecutive days. We were therefore limited by our 
inability to attract volunteers who would undergo daily blood sampling and transvaginal 
ultrasonography in this protocol. In addition, it was financially untenable to have a separate 
control group in this study for each treatment group. 
In summary, letrozole treatment at follicle diameters of 12 mm or 18 mm or 24 
hours post OV were associated with transient decrease in E2 levels and elevated circulating 
FSH and LH concentrations for 4 days following treatment. The drop in E2 concentration 
did not suppress dominant follicle growth or early CL development. These results were 
unexpected and provide an impetus for additional studies to elucidate the roles of E2, LH, 
and FSH in the regulation of follicle and luteal development in women. 
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Chapter 6:  General Discussion 
 Men and women have been working to control fertility with many forms of 
contraception and methods to enhance fertility for thousands of years (295, 296). The 
available methods have been improved greatly because of the demand for safe, effective 
therapies. There are increasing numbers of women utilizing contraception to prevent 
pregnancy or assisted reproductive technologies to conceive (297, 298). Though the demand 
for manipulation and control of ovarian function is increasing, most women, as well as 
scientists and clinicians, do not completely understand the menstrual cycle (299). The ovary 
is the “master” gland of female reproductive function. An understanding of ovarian function 
is integral to comprehending reproductive function. The social stigma and personal 
embarrassment commonly associated with an inability to adequately control reproductive 
processes may prevent many individuals from becoming informed about their own 
reproductive physiology and possible contraceptive and fertility therapy choices.   
 Letrozole, a non-steroidal aromatase inhibitor (AI), is used as an adjuvant therapy for 
hormone sensitive breast cancer in post-menopausal women (300-302). Aromatase inhibitors 
work through systemic inhibition of aromatase to reduce the amount of circulating estrogen 
(178, 181, 275, 276, 300-304). In pre-menopausal women, AI have been administered in 
fertility treatments for the purpose of follicular stimulation, ovulation (OV) induction, and 
ovarian super-stimulation (51, 203, 206, 207). Letrozole in fertility therapies is administered 
before follicular dominance is manifest. Administration before follicular selection has been 
reported to have a stimulatory effect on ovarian function that is mediated by increased 
follicle stimulating hormone (FSH) secretion (286). The treatment goals for fertility therapy 
include follicle development, OV and clinical pregnancy.  
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It has been proposed that letrozole administration before follicle selection eliminates 
the negative feedback of estradiol (E2) on the hypothalamus/pituitary axis (43, 46, 182, 197). 
Release of negative feedback induces a rise in circulating FSH concentrations (43, 46, 182, 
197). This extends the growth phase of the follicles in the extant wave. However, the effects 
of AI on follicular dynamics in women do not appear to have been critically determined in 
any scientific reports. We hypothesized that AI treatment after follicle selection would have a 
suppressive effect on extant follicle development. Dominant follicle suppression could result 
in a rise in FSH secretion and subsequent emergence of a new follicular wave. We conducted 
an experiment to determine the effects of administering a single large administration of 
letrozole on follicular dynamics post selection (12 mm), peri-OV (18 mm), and post-OV 
(Chapter 6). The study reported in this thesis failed to show that a single large dose of 
letrozole at the specific points of post selection follicle growth would induce the regression 
of the dominant follicle and the emergence of a new follicular wave. Conversely, 
administration of AI peri-selection of a dominant follicle resulted in continued follicle 
growth, OV, a transient drop in E2 concentrations and a prolonged rise in FSH and 
luteinizing hormone (LH) concentrations. 
Contrary to our hypothesis, letrozole treatment did not result in extant follicle 
regression and new wave emergence. This finding is in contrast to reports of oral 
contraception (OC) initiation at 10 mm and 14 mm follicle diameters (34). Initiation of oral 
contraception (OC) at a follicular diameter of 10 mm (i.e., at selection) resulted in continued 
growth followed by regression (34). The observations from initiation of OC at 10 mm and 
14 mm follicles are consistent with reports of follicle growth following AI treatment in 
heifers (277, 282). Administration of OC at a 14 mm follicle only resulted in OV in 36% of 
cases in women (34) versus OV in 100% of participants in the 12 mm group of the present 
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study. The differences in post selection follicle growth following temporary E2 suppression 
or exogenous estrogen availability could result from distinct rescue mechanisms. The 
disparity between follicle growth patterns following OC initiation and AI treatment initiation 
are compelling reasons to have included a pre-selection AI treatment group. The differences 
in follicle growth, with or without E2, and before or after selection indicate there are 
probably multiple mechanisms involved in rescuing follicles from initiating atresia. 
Although E2 production decreased following treatment, follicle growth continued 
and the dominant follicles in the immediate post selection (12 mm) and peri-OV (18 mm) 
treatment groups ovulated. Letrozole treatment did not affect the growth rate of the pre-
ovulatory follicle or interval from menses OV (Chapter 6). The growth rates of all treatment 
groups follicles were similar to reported follicle growth rates in natural, oral contraceptive 
and fertility stimulation cycles (261). The lifespan of the dominant follicle was extended with 
a single dose and 3 day AI dosing administration in heifers (277, 282). The results are 
consistent with reported observations of follicle development following OC initiation at a 14 
mm or 18 mm follicle diameter (34). The dramatic drop in E2 with letrozole treatment and 
the exogenous rise in estrogen with OC initiation were both associated with increased LH 
levels. However, in the absence of E2 it appears that a rise in circulating LH concentrations 
may play a more prominent role in follicle survival.  
Some women treated with letrozole early in the follicular phase (treatment initiation 
on day 3 of the menstrual cycle) grew two dominant follicles to ovulatory status (45, 48, 201, 
206, 208, 214, 215, 287, 294, 305). Treatment immediately post selection in our study 
resulted in double OV in 20% of the treatment group. The mechanism may be due to LH 
responsiveness in subordinate follicles at the time of selection (306). Synchronous 
development of 2 follicles also was observed in heifers following post-OV AI treatment 
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(277). In the bovine model it has been shown that if the dominant follicle is removed a 
subordinate follicle is capable of assuming dominance (307). Therefore, some subordinate 
follicles may be slightly LH responsive; an elevation in LH post treatment may have 
stimulated the growth of the largest subordinate follicle. Another mechanism that could have 
resulted in the survival of the largest subordinate follicle is an increase in follicular fluid 
androgen levels following AI administration. Androstenedione levels increased in the 
follicular fluid of Rhesus monkeys treated with an AI (150) and circulating androgen levels 
increased in women given letrozole treatment (214, 293). In bonnet monkeys, increases in 
androgen levels amplified FSH receptor (FSHr) numbers and increased the sensitivity of the 
developing follicle to available circulating FSH (196). Though androgen levels were not 
tested in the serum collected in this thesis, an increase in androgen levels following letrozole 
treatment would not be unexpected and would allow for increased FSHr and increased 
sensitivity of all viable follicles to the rise in circulating FSH. 
 Letrozole treatment at different biologically important times in follicle growth has 
similar effects on LH secretion but differential effects on FSH secretion. The peak in LH 
occurred quickly in all treatment groups, while the peak in FSH occurred on a different day 
in all treatment groups. The immediate reasons for the difference in response remains poorly 
elucidated; however, induction of an E2 decrease at varying stages of follicle growth and the 
subsequent increases in androgens and P4 could account for the differences in the pituitary 
response. The prevailing convention in AI treatment for ovulation induction in fertility 
therapy is to evaluate gonadotrophins before treatment and after human chorionic 
gonadotropin (hCG) injection (45, 198, 202, 204, 206, 208, 308). Elevated LH 
concentrations, but no elevation in FSH concentrations, were observed on the last day of a 5 
day pre-selection letrozole treatment (305). On day 6 of a 7 day pre-selection treatment 
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regimen, an overall higher mean LH concentration was found in letrozole treated women 
compared to controls (293). Thus, even before dominant follicle selection, AI treatment 
affected LH and FSH secretion differentially. 
 A rise in LH secretion the day following letrozole treatment was observed in all 
treatment groups. In the 18 mm treatment group the rise in LH resulted in OV of the follicle 
at a mean of 42 hours after treatment compared with 72 hours in the control group. The 
consistent interval observed from treatment to OV may be interpreted to mean that there is 
a potential use for AI in inducing an LH surge. Administration of a single dose of AI at pre-
ovulatory follicle diameters could reduce fertility patient exposure to exogenous hormones 
by reducing the need for FSH, hCG, or GnRH agonist/antagonists. Following AI treatment 
in the 12 mm group a natural LH surge occurred to induce OV of the pre-ovulatory sized 
follicle. A natural LH surge at pre-ovulatory follicle size has also been shown to occur 
following AI treatment administered before follicle selection (196, 204, 305, 308). The 
observation of a continued follicle growth following a single treatment of letrozole at a 12 
mm follicle in normally cycling women indicates a new potential treatment for infertility 
patients.  Combining 2 large doses given on day 3 of the menstrual cycle and at the 
observance of a 12 mm follicle is a potential way to reduce the need for exogenous FSH 
injections and prevent ovarian hyperstimulation. 
 There does not appear to be an effect of AI on endometrial morphology. Following 
early single dose and 5 day dosing schemes, endometrial thickness and pattern did not differ 
from controls mid-cycle (198, 202, 204, 206, 294, 309). Mid-cycle there were no difference in 
endometrial pattern or thickness in the present study (Chapter 6). There have been reports 
of the endometrium of letrozole treated women being thinner in the mid-follicular phase but 
having recovered to levels of non-letrozole treated patients by the time of hCG 
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administration (309). Thicker mid-cycle endometrial linings have been reported in women 
taking a 5 day treatment of 7.5 mg/day compared to women taking 2.5 or 5 mg/day (208). 
In our study, the endometrial thickness of all experimental groups did not differ throughout 
the menstrual cycle. However, women in the 12 mm treatment group reached a D pattern 
endometrial morphology earlier than women in the other 3 experimental groups (Chapter 6). 
Thus, there appears to be a mechanism that allows the endometrium to compensate for a 
decrease in E2 throughout the menstrual cycle. 
 Letrozole affected ovarian function in an unexpected way. Inhibition of E2 with an 
AI post-selection of a dominant follicle increased release of FSH and LH. The increase in 
LH concentrations resulting from AI treatment may have aided continued growth of the 
extant dominant follicle and allowed OV to occur without the need for hCG treatment when 
a pre-ovulatory follicle diameter was reached. Further, the rise in LH following 
administration of AI at a pre-ovulatory follicle diameter stimulated OV earlier than 
anticipated. We have proposed a new mechanism of action for AI on ovarian function 
following DF selection involving increased endogenous levels of LH and FSH. Aromatase 
inhibitors represent a potentially safe way to reduce the exposure of women to exogenous 
steroids and gonadotropins during fertility therapy. 
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Chapter 7:  General Conclusion 
 The result of the experiment included in this thesis and the related literature have led 
to the conclusion that a single 20 mg dose of letrozole did not cause ovulatory failure or 
failure of CL formation by suppressing E2 production. Subsequently, letrozole treatment did 
not arrest endometrial development, shorten the interval between menses, or initiate new 
follicular wave emergence. The results of our study are supportive of an alternative 
hypothesis regarding the control of folliculogenesis through a transient increase in LH 
secretion following Letrozole treatment presented in the literature (277, 278, 282). 
 The specific conclusions of this thesis are: 
1. Letrozole given once orally at a dose of 20 mg in pre-menopausal, norm-ovulatory 
women does not reduce dominant follicle growth or cause ovulatory failure 
regardless of the stage of development at treatment; 
2. A single, oral dose of 20 mg of letrozole in pre-menopausal, normo-ovulatory 
women did not alter the formation of the CL as observed by the similar mean P4 
levels, IMI and IOI; 
3. Letrozole treatment given as a single oral dose of 20 mg in pre-menopausal, normo-
ovulatory women causes a transient decrease in E2 and increased circulating FSH and 
LH concentrations regardless of the stage of follicle development at treatment; 
and, 
4. Higher circulating LH concentration following a single, 20 mg oral dose of letrozole 
in pre-menopausal normo-ovulatory women can stimulate continued growth of the 
dominant follicle. 
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